Patent Application
20090196912
The present invention relates to pyridinylamines and pharmaceutically acceptable salts thereof, the use of these compounds for the prophylaxis and/or treatment of various diseases such as infectious diseases, including infectious diseases and opportunistic infections, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as compositions containing at least one pyridinylamine and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of said pyridinylamines are disclosed.
Object of the present invention is to provide pharmaceutically active compounds for prophylaxis and treatment of various diseases such as infections, inflammations, immunological diseases, cardiovascular diseases, cell proliferative diseases, transplant rejections, or neurodegenerative diseases, methods for the synthesis of said compounds and pharmaceutical compositions containing at least one pharmaceutically active compound.
This object is solved by the pyridinylamines as described herein below, and/or pharmaceutically acceptable salts of said compounds, the use of at least one of those compounds and/or the pharmaceutically acceptable salts thereof as pharmaceutically active agents as described herein below, the use of the compounds as an inhibitor for a protein kinase as described herein below, the use of the compounds for prophylaxis and/or treatment of various diseases as described herein below, and the pharmaceutical composition as described herein below. Further advantageous features, aspects and details of the invention are evident from the claims, the description, the examples and the drawings.
One aspect of the present invention is related to compounds of the general formula (I):
represents one of the following moieties:
In another aspect, the present invention is related to compounds of the general formula (I):
represents one of the following moieties:
Yet another aspect of the present invention is related to compounds as described above wherein the following compounds are not encompassed:
Yet another aspect of the present invention is related to compounds as described above wherein additionally the following compounds are not encompassed:
Of the compounds of the invention as described above, a preferred group are those compounds of the general formula (II)
wherein
the substituents R2, R3, R23-R27 have the meanings as defined above.
Another preferred group according to the present invention are those compounds of the general formula (III)
wherein
the substituents R1, R2, R4 have the meanings as defined above.
Another preferred group according to the present invention are those compounds of formulae (I), (II) or (III), wherein
where n is zero;
where n is zero;
Of this group of compounds, a more preferred subgroup according to the present invention are those compounds wherein
Of the above subgroup of compounds, a more preferred class of compounds according to the present invention are those compounds wherein:
A preferred subclass of compounds of the above class is that subclass wherein:
Of the above subclass even more preferred are compounds wherein
Of the above subgroup of compounds, another more preferred class of compounds according to the present invention are those compounds wherein:
Another preferred subgroup of compounds according to the present invention are those compounds of general formulae (I), (II) or (III) wherein:
—CR35R36R37, —X—(CH2)m—CR32R33R34, or —X—CH2—R51;
Of this subgroup, a preferred class of compounds according to the invention are those compounds wherein:
Another preferred subgroup of compounds according to the present invention are those compounds of general formulae (I), (II) or (III) wherein:
—CR—R
30R
, —X—(CH2)m—CR32R33R34, or —X—CH2—R51;
Of the above subgroup of compounds, a more preferred class of compounds according to the present invention are those compounds wherein:
—CR35R36R37, —X—(CH2)m—CR32R33R34, or —X—CH2—R51.
Another preferred subgroup of compounds according to the present invention are those compounds of general formulae (I), (II) or (III) wherein:
or —X—(CH2)m—CR32R33R34, —X—CH2—R51;
Of the above subgroup of compounds, a more preferred class of compounds according to the present invention are those compounds wherein:
or —X—(CH2)m—CR32R33R34, —X—CH2—R51.
Another preferred subgroup of compounds according to the present invention are those compounds of general formulae (I), (II) or (III) wherein:
Of the above subgroup of compounds, a more preferred class of compounds according to the present invention are those compounds wherein:
In another aspect of the invention, those compounds of the formulae (I), (II), or (III), or according to any one of the above groups, subgroups, classes or subclasses are preferred wherein R7 is not hydrogen.
In another aspect of the invention, those compounds of the formulae (I), (II), or (III), or according to any one of the above groups, subgroups, classes or subclasses are preferred wherein R7 is not hydrogen and not hydroxy.
In yet another aspect of the invention, those compounds of the formulae (I), (II), or (III), or according to any one of the above groups, subgroups, classes or subclasses are preferred wherein R23 is not hydrogen.
In yet another aspect of the invention, those compounds of the formulae (I), (II), or (III), or according to any one of the above groups, subgroups, classes or subclasses are preferred wherein R23 is not hydrogen, not methoxy and not hydroxymethyl.
In yet another aspect of the invention, those compounds of the formulae (I), (II), or (III), or according to any one of the above groups, subgroups, classes or subclasses are preferred wherein R8 is not —F, —Cl, —OH, or —OCH3.
In yet another aspect of the invention, those compounds of the formulae (I), (II), or (III), or according to any one of the above groups, subgroups, classes or subclasses are preferred wherein R8 is not —F, —Cl, —Br, —NH2, —NO2, —OH, —OCH3, Or-OCF3.
In yet another aspect of the invention, those compounds of the formulae (I), (II), or (III), or according to any one of the above groups, subgroups, classes or subclasses are preferred wherein R9 is not —F, —Cl, or —OCH3.
In yet another aspect of the invention, those compounds of the formulae (I), (II), or (III), or according to any one of the above groups, subgroups, classes or subclasses are preferred wherein R9 is not —F, Cl, —Br, —NH2, —NO2, —OH, or —OCH3.
In yet another aspect of the invention, those compounds of the formulae (I), (II), or (III), or according to any one of the above groups, subgroups, classes or subclasses are preferred wherein R9 is not —F, —Cl, —Br, —NH2, —N(CH3)2, —NO2, —OH, or —OCH3.
Other preferred substructures are selected from the following formulas (IV-XVII):
wherein
the substituents R1-R4 and R23-R27 have the meanings as defined above.
Especially the following compounds are preferred:
Most of the compounds of the invention are basic and form pharmaceutically acceptable salts with organic and inorganic acids.
Examples of suitable acids for such acid addition salt formation are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, p-toluenesulfonic acid, naphthylsulfonic acid, sulfanilic acid, camphersulfonic acid, china acid, mandelic acid, o-methylmandelic acid, hydrogen-benzenesulfonic acid, picric acid, adipic acid, D-o-tolyltartaric acid, tartronic acid, α-toluic acid, (o, m, p)-toluic acid, naphthylamine sulfonic acid, and other mineral or carboxylic acids well known to those skilled in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner.
The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium hydroxide, potassium carbonate, ammonia and sodium bicarbonate. The free base forms differ from their corresponding salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the salts are otherwise equivalent to their corresponding free base forms for purposes of this invention.
The present invention also comprises pharmaceutically active salts of these compounds, all stereoisomeric forms and regioisomeric forms of these compounds or prodrugs thereof.
Other aspects of the present invention relate to the pyridinylamines as outlined above in the general formula (I), for use as new pharmaceutically active agents, particularly for the prophylaxis and/or treatment of prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases, stroke, hair loss, obesity, polycystic ovary syndrome, ischaemia leukopenia, Down's syndrome, Lewy body disease, Crohns disease, periodontal diseases, corneal ulceration, proteinuria, myelodysplastic syndromes, biliary cirrhosis, virally or bacterially induced diseases or infections, mycobateria-induced infections (including opportunistic infections) and diseases, pharmaceutical compositions comprising these pyridinylamines as active ingredients and methods for treating prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases, stroke, viral infections, virally and/or bacterially induced diseases, in mammals, including humans.
Surprisingly, it was found that the compounds according to general formula (I) as well as pharmaceutically acceptable salts of these compounds can be used for prophylaxis and/or treatment of prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases, stroke, hair loss, obesity, polycystic ovary syndrome, ischaemia leukopenia, Down's syndrome, Lewy body disease, periodontal diseases, corneal ulceration, proteinuria, myelodysplastic syndromes and biliary cirrhosis, virally and/or bacterially induced diseases, especially mycobacteria-induced infections and diseases at pharmaceutically acceptable concentrations while exhibiting enhanced metabolitic stability. It shall be stressed that the compounds which are excluded from the claims by disclaimer are herewith explicitly claimed for any pharmaceutical use thereof as described herein.
Furthermore, it was found the pyridinylamines of the present invention are kinase inhibitors, especially of tyrosine kinases and tyrosine-like kinases.
Protein kinases form a large family of structurally related enzymes that control a variety of different cell processes including proliferation, differentiation, apoptosis, motility, transcription, translation and other signaling processes by adding phosphate groups to target proteins (Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Book, I and II, Academic Press, San Diego, Calif.). The protein kinase family can conveniently be classified into two classes with regard to substrate specificity: protein tyrosine kinases (PTKs) phosphorylate their substrates on tyrosine residues, whereas serine/threonine kinases (STKs) phosphorylate proteins on serine or threonine residues.
PTKs can be further subdivided into receptor tyrosine kinases (RTKs) and intracellular tyrosine kinases. Upon binding of a ligand like a growth factor or hormone, RTKs are activated and, in turn, affect numerous cellular responses such as cell division (proliferation), cell differentiation, cell growth, expression of metabolic enzymes, effects to the extracellular microenvironment, etc. An example of a RTKs is the “HER” family of RTKs, which include EGFR (epithelial growth factor receptor), HER2, HER3 and HER4. Further examples include the PDGFR family, c-Kit, and others.
Intracellular tyrosine kinases do not contain extracellular and transmembrane domains. One example of this group is the Abl tyrosine kinase, whose fusion with the BCR-gene is the cause for chronic myelogenous leukaemia (Semin Hematol. 2003 April; 40(2 Suppl 2):4-10).
Related to ABL is the Src family of intracellular tyrosine kinases. These kinases are implicated in cancer, immune system dysfunction and bone remodeling diseases (For general reviews, see Thomas and Brugge, Annu. Rev. Cell Dev. Biol. (1997) 13, 513; Lawrence and Niu, Pharmacol. Then (1998) 77, 81; Tatosyan and Mizenina, Biochemistry (Moscow) (2000) 65, 49; Boschelli et al., Drugs of the Future 2000, 25(7), 717, (2000)).
Members of the Src family include the following eight kinases in mammals: Src, Fyn, Yes, Fgr, Lyn, Hck, Lck, and Blk. Based on published studies, Src kinases are considered as potential therapeutic targets for various human diseases. Mice that are deficient in Src develop osteoporosis, or bone build-up, because of depressed bone resorption by osteoclasts. This suggests that osteoporosis resulting from abnormally high bone resorption can be treated by inhibiting Src (Soriano et al., Cell, 69, 551 (1992) and Soriano et al., Cell, 64, 693 (1991)).
Src also plays a role in the replication of hepatitis B virus. The virally encoded transcription factor HBx activates Src in a step required for propagation of the virus (Klein et al., EMBO J., 18, 5019, (1999) and Klein et al., Mol. Cell. Biol., 17, 6427 (1997)).
A number of studies have linked Src expression to cancers such as colon, breast, hepatic and pancreatic cancer, certain B-cell leukemias and lymphomas (Curr Pharm Des. 2003; 9(25):2043-59; Front Biosci. 2003 Sep. 1; 8:s1068-73).
Other Src family kinases are also potential therapeutic targets. The function of Lck as a positive activator of T-cell signaling suggests that Lck inhibitors may be useful for treating autoimmune disease such as rheumatoid arthritis (Molina et al., Nature, 357, 161 (1992)). Hck, Fgr and Lyn have been identified as important mediators of integrin signaling in myeloid leukocytes (Lowell et al., J. Leukoc. Diol., 65, 313 (1999)). Inhibition of these kinase mediators may therefore be useful for treating inflammation (Boschelli et al., Drugs of the Future 2000, 25(7), 717, (2000)).
An example for a STK family kinase is RICK (RIP2, Cardiak, CARD3). RICK belongs to the RIP family of protein kinases, including the kinases RICK, RIP, Rip3 and RIP4, which have been implemented in NF-kB activation. RICK is central part of the innate and adaptive immune response and involved in host response to intracellular infections as well as in inflammatory processes (Eickhoff et al. JBC March 2003; Current Biology, 8, p. 885-8; Nature 416, p. 194-9; Nature 416, p. 190-3.). Inhibition of RICK has been described to modulate the innate and adaptive immune response (WO03059285). Inhibitors of RICK and RIP kinase activity have been described to block human Cytomegalovirus replication (US20030082519). The inventive compounds are explicitly suitable as RICK inhibitors.
ROCK1 and 2 constitute a family of kinases that have been shown to be involved in cellular functions including apoptosis, cell migration, transcriptional activation, fibrosis, cytokinesis, inflammation and cell proliferation (Nat Rev Mol Cell Biol. 2003 June; 4(6):446-56). Moreover, ROCK plays a critical role in smooth muscle contraction and in the inhibition of axonal growth in neurons. Therefore, ROCK1 and 2 have been implicated to be important for a number of diseases (Curr Opin Investig Drugs. 2003 September; 4(9):1065-75; Int J Impot Res. 2003 October; 15 Suppl 5:S20-4.). Inhibition of Rho kinase activity in animal models has demonstrated a number of benefits of Rho kinase inhibitors for atherosclerosis, cardiovascular diseases such as hypertension, penile erectile dysfunction, central nervous system disorders, neoplasias, thrombotic disorders such as platelet aggregation, leukocyte aggregation and bone resorption.
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase, comprised of alpha and beta isoforms, that has been linked to various diseases including diabetes, Alzheimer's disease, CNS disorders such as manic depressive disorder and neurodegenerative diseases, and cardiomyocyte hypertrophy [see, e.g., WO 99/65897; WO 00/38675; Kaytor and Orr, Curr. Opin. Neurobiol., 12, 275-8 (2000); Haq et al., J. Cell Biol., 151, 117-30 (2000); Eldar-Finkelman, Trends Mol. Med., 8, 126-32 (2002)].
Another example for a serine/threonine kinase is Inhibitor of NF-kappa B kinase beta (IKK beta). Included in the genes regulated by NF-kappa B are a number of cytokines and chemokines, cell adhesion molecules, acute phase proteins, immunoregulatory proteins, eicosanoid metabolizing enzymes and anti-apoptotic genes (Cell. 2002 April; 109 Suppl:S81-96). It is well-known that NF-kappa B plays a key role in the regulated expression of a large number of pro-inflammatory mediators including cytokines such as TNF, IL-1 beta, IL-6 and IL-8, cell adhesion molecules, such as ICAM and VCAM, and inducible nitric oxide synthase (iNOS). Several IKK beta inhibitors are currently being in development for the treatment of a variety of inflammatory and autoimmune diseases (Nat Rev Drug Discov. 2004 January; 3(1): 17-26).
Among the kinases, the cyclin-dependent kinases (CDKs) play a major role in the control of the cell cycle. To date, nine kinase subunits (cdk 1-9) have been identified along with several regulatory subunits (cyclins A-H) (A. M. Senderowicz and E. A. Sausville Journal of the National Cancer Institute (2000), 92 (5), 376-387; and S. Mani; C. Wang; K. Wu; R. Francis; R. Pestell ‘Exp. Opin. Invest. Drugs (2000) 9 (8), 1849-1870). An increasing body of evidence has shown a link between tumour development and cdk related malfunctions. CDKs play a role in the regulation of cellular proliferation. Therefore, CDK inhibitors could be useful in the treatment of cell proliferative disorders (Lancet Oncol. 2004 January; 5(1):27-36. Review, Oncogene. 2003 Sep. 29; 22(42):6609-20, Curr Opin Pharmacol. 2003 August; 3(4):362-70.). Other indications include neurodegenerative disorders such as Alzheimer's disease and amyotrophic lateral sclerosis, which have been linked to Cdk5 (J Mol Neurosci. 2002 December; 19(3):267-73). Several host cell kinases have been shown to be important for virus replication like human cytomegalovirus, herpes simplex virus, human immune deficiency virus and VCV varicella zoster virus (WO2004/043467).
p38 is another example for a protein kinase with serine/threonine specificity. It is also known as cytokine suppressive anti-inflammatory drug binding protein (CSBP). Inhibition of p38 kinase leads to a blockade in the production of both IL-1 and TNF. Based upon this finding it is believed that p38, along with other MAPKs, has a role in mediating cellular responses to inflammatory stimuli, such as leukocyte accumulation, macrophage/monocyte activation, tissue resorption, fever, acute phase responses and neutrophilia. In addition, p38 has been implicated in acute and chronic inflammatory diseases, in cancer, thrombin-induced platelet aggregation, immunodeficiency disorders, autoimmune diseases, cell death, allergies, osteoporosis and neurodegenerative disorders (WO9621654; Current review: p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003 September; 2(9):717-26).
The human cytomegalovirus-encoded protein kinase pUL97 is belonging to a group of homologous protein kinase C (PKC)-like protein kinases with serine/threonine-specificity. Several studies have shown that pUL97 is particularly important for efficient replication (Marschall et al., 2001; Michel et al., 1996; Prichard et al., 1999; Wolf et al., 2001). Inhibitors of pUL97 should therefore be useful for treatment of HCMV associated diseases.
It has been clearly demonstrated that kinases play an important role in disease states associated with, but not limited to, disregulated cell signaling, inflammation, cancer, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system, and angiogenesis. The development of selective protein kinase inhibitors that can block the disease pathologies and/or symptoms resulting from aberrant protein kinase activity has therefore generated much interest (Current review: Protein kinases—the major drug targets of the twenty-first century? Nat Rev Drug Discov. 2002 April; 1(4):309-15). Attempts have been made to identify small organic molecules which inhibit protein kinases. For example, imidazoles, oxazoles and thiazoles (WO2004/005283), purines (2003/0199534) and bisindolyl-maleimids (WO9718809) have been described as kinase inhibitors. 3-(cycloalkano-heteroarylidenyl)-2-indolinone (U.S. Pat. No. 6,579,897), pyrimido-pyrimidines (US20040019210) and bis-monocylic, bicyclic and heterocyclic aryl compounds (WO 92/20642) have been described as specific PTK inhibitors. Some companies have begun to develop Inhibitors that specifically inhibit p38. For example, PCT publication WO02/14281 describes purines, PCT publication WO95/31451 describes pyrazoles and US 2004/0023992 describes pyrazolo-pyrimidine aniline compounds as p38 inhibitors. PCT publication WO 98/27098 also describes substituted nitrogen-containing heterocycles as p38 inhibitors. Heteroaryls, covering substituted 3-aminopyridines amongst others, are described as Akt kinase inhibitor agents (WO 03/051366) with no biological activity shown on other kinases.
The following list represents a certain number of kinases which can be inhibited by the inventive compounds:
Additionally, the present invention relates to the use of the compounds of the present invention for the manufacturing of a pharmaceutical composition for the prophylaxis and/or treatment of prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases, stroke, virally and/or bacterially induced diseases.
Further aspects of the present invention relate to the use of the compounds of general formula (I) for the preparation of a pharmaceutical composition useful for prophylaxis and/or treatment of infectious diseases including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, osteoporosis, transplant rejections, erectile dysfunction, neurodegenerative diseases, stroke, hair loss, obesity, polycystic ovary syndrome, ischaemia leukopenia, Down's syndrome, Lewy body disease, periodontal diseases, corneal ulceration, proteinuria, myelodysplastic syndromes and biliary cirrhosis.
In yet another aspect of the present invention, the compounds according to the general formula (I) are for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases and opportunistic infections. The term infectious diseases comprises infections caused by viruses, bacteria, prions, fungi, and/or parasites.
Especially, virally induced infectious diseases, including opportunistic diseases are addressed. In a preferred embodiment of this aspect, the virally induced infectious diseases, including opportunistic diseases, are caused by retroviruses, human endogenous retroviruses (HERVs), hepadnaviruses, herpesviruses, flaviviridae, and/or adenoviruses. Preferably, the retroviruses are selected from lentiviruses or oncoretroviruses, wherein the lentivirus is preferably selected from the group comprising: HIV-1, HIV-2, feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), sivian immunodeficiency viruses (SIVs), chimeras of HIV and SIV (SHIV), caprine arthritis encephalitis virus (CAEV), visna/maedi virus (VMV) or equine infectious anemia virus (EIAV), preferably HIV-1 and HIV-2, and the oncoretrovirus is preferably selected from HTLV-I, HTLV-II or bovine leukemia virus (BLV), preferably HTLV-I and HTLV-II.
The hepadnavirus is preferably selected from HBV, ground squirrel hepatitis virus (GSHV) or woodchuck hepatitis virus (WHV), preferably HBV, the herpesvirus is selected from the group comprising: Herpes simplex virus I (HSV I), herpes simplex virus II (HSV II), Epstein-Barr virus (EBV), varicella zoster virus (VZV), human cytomegalovirus (HCMV), human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7) or human herpesvirus 8 (HHV-8), preferably HCMV, and the flaviviridae is selected from HCV, West nile or Yellow Fever.
It is to be understood, that all the viruses mentioned above, also comprise drug resistant virus strains.
Examples of infective diseases are AIDS, Alveolar Hydatid Disease (AHD, Echinococcosis), Amebiasis (Entamoeba histolytica Infection), Angiostrongylus Infection, Anisakiasis, Anthrax, Babesiosis (Babesia Infection), Balantidium Infection (Balantidiasis), Baylisascaris Infection (Raccoon Roundworm), Bilharzia (Schistosomiasis), Blastocystis hominis Infection (Blastomycosis), Boreliosis, Botulism, Brainerd Diarrhea, Brucellosis, BSE (Bovine Spongiform Encephalopathy), Candidiasis, Capillariasis (Capillaria Infection), CFS (Chronic Fatigue Syndrome), Chagas Disease (American Trypanosomiasis), Chickenpox (Varicella-Zoster virus), Chlamydia pneumoniae Infection, Cholera, Chronic Fatigue Syndrome, CJD (Creutzfeldt-Jakob Disease), Clonorchiasis (Clonorchis Infection), CLM (Cutaneous Larva Migrans, Hookworm Infection), Coccidioidomycosis, Conjunctivitis, Coxsackievirus A16 (Hand, Foot and Mouth Disease), Cryptococcosis, Cryptosporidium Infection (Cryptosporidiosis), Culex mosquito (Vector of West Nile Virus), Cutaneous Larva Migrans (CLM), Cyclosporiasis (Cyclospora Infection), Cysticercosis (Neurocysticercosis), Cytomegalovirus Infection, Dengue/Dengue Fever, Dipylidium Infection (Dog and Cat Flea Tapeworm), Ebola Virus Hemorrhagic Fever, Echinococcosis (Alveolar Hydatid Disease), Encephalitis, Entamoeba coli Infection, Entamoeba dispar Infection, Entamoeba hartmanni Infection, Entamoeba histolytica Infection (Amebiasis), Entamoeba polecki Infection, Enterobiasis (Pinworm Infection), Enterovirus Infection (Non-Polio), Epstein-Barr Virus Infection, Escherichia coli Infection, Foodborne Infection, Foot and mouth Disease, Fungal Dermatitis, Gastroenteritis, Group A streptococcal Disease, Group B streptococcal Disease, Hansen's Disease (Leprosy), Hantavirus Pulmonary Syndrome, Head Lice Infestation (Pediculosis), Heliobacter pylori Infection, Hematologic Disease, Hendra Virus Infection, Hepatitis (HCV, HBV), Herpes Zoster (Shingles), HIV Infection, Human Ehrlichiosis, Human Parainfluenza Virus Infection, Influenza, Isosporiasis (Isospora Infection), Lassa Fever, Leishmaniasis, Kala-azar (Kala-azar, Leishmania Infection), Leprosy, Lice (Body lice, Head lice, Pubic lice), Lyme Disease, Malaria, Marburg Hemorrhagic Fever, Measles, Meningitis, Mosquito-borne Diseases, Mycobacterium avium Complex (MAC) Infection, Naegleria Infection, Nosocomial Infections, Nonpathogenic Intestinal Amebae Infection, Onchocerciasis (River Blindness), Opisthorciasis (Opisthorcis Infection), Parvovirus Infection, Plague, PCP (Pneumocystis carinii Pneumonia), Polio, Q Fever, Rabies, Respiratory Syncytial Virus (RSV) Infection, Rheumatic Fever, Rift Valley Fever, River Blindness (Onchocerciasis), Rotavirus Infection, Roundworms Infection, Salmonellosis, Salmonella Enteritidis, Scabies, Shigellosis, Shingles, Sleeping Sickness, Smallpox, Streptococcal Infection, Tapeworm Infection (Taenia Infection), Tetanus, Toxic Shock Syndrome, Tuberculosis, Ulcers (Peptic Ulcer Disease), Valley Fever, Vibrio parahaemolyticus Infection, Vibrio vulnificus Infection, Viral Hemorrhagic Fever, Warts, Waterborne infectious Diseases, West Nile Virus Infection (West Nile Encephalitis), Whooping Cough, Yellow Fever, Charga's disease, effects of Shiga-like toxin resulting from Staphylococcus infection, meningococcal infection, infections from Borrelia burgdorferi, Treponema pallidum.
As described above, the compounds according to the general formula (I) are also useful for the preparation of a pharmaceutical composition for prophylaxis and/or treatment of bacterially induced infectious diseases, including opportunistic diseases and opportunistic infections, wherein the bacterially induced infectious diseases, including opportunistic diseases, are selected from tuberculosis, leprosy or mycobacteria-induced meningitis. One advantage of the inventive compounds disclosed herein is there use against drug resistant bacterial strains.
Another aspect of the present invention is directed to the use of at least one compound of the general formula (I) and/or pharmaceutically acceptable salts thereof for prophylaxis and/or treatment of prion diseases.
Prions are infectious agents, which do not have a nucleic acid genome. It seems that a protein alone is the infectious agent. A prion has been defined as “small proteinaceous infectious particle, which resists inactivation, by procedures that modify nucleic acids”. The discovery that proteins alone can transmit an infectious disease has come as a considerable surprise to the scientific community. Prion diseases are often called “transmissible spongiform encephalopathies”, because of the post mortem appearance of the brain with large vacuoles in the cortex and cerebellum. Probably most mammalian species develop these diseases. Prion diseases are a group of neurodegenerative disorders of humans and animals and the prion diseases can manifest as sporadic, genetic or infectious disorders.
As used herein the term “prion diseases” refers to transmissible spongiform encephalopathies. Examples for prion diseases acquired by exogenous infection are the Bovine spongiform encephalitis (BSE) of cattle and cows and the new variant of Creutzfeld-Jakob disease (vCJD) caused by BSE as well as scrapie (sheep, goat), TME (transmissible mink encephalopathy; mink), and CWD (chronic wasting disease; muledeer, deer, elk) of animals. Examples of human prion diseases include kuru, Alpers Syndrome, sporadic Creutzfeldt-Jakob disease (sCJD), familial CJD (fCJD), iatrogenic CJD (iCJD), Gerstmann-Straussler-Scheinker (GSS) disease, fatal familial insomnia (FFI), and especially the new variant CJD (nvCJD or vCJD). Preferred are BSE, vCJD, and CJD.
The name “prion” is used to describe the causative agents, which underlie the transmissible spongiform encephalopathies. A prion is proposed to be a novel infectious particle that differs from viruses and viroids. It is composed solely of one unique protein that resists most inactivation procedures such as heat, radiation, and proteases. The latter characteristic has led to the term protease-resistant isoform of the prion protein. The protease-resistant isoform has been proposed to slowly catalyze the conversion of the normal prion protein into the abnormal form.
The term “isoform” in the context of prions means two proteins with exactly the same amino acid sequence, that are folded into molecules with dramatically different tertiary structures. The normal cellular isoform of the prion protein (PrPc) has a high a-helix content, a low b-sheet content, and is sensitive to protease digestion. The abnormal, disease-causing isoform (PrPSc) has a lower a-helix content, a much higher b-sheet content, and is much more resistant to protease digestion.
Another aspect of the present invention is directed to the use of at least one compound of the general formula (I) and/or pharmaceutically acceptable salts thereof for prophylaxis and/or treatment of immunological diseases, neuroimmunological diseases, and autoimmune diseases.
Immunological diseases are, for instance, asthma and diabetes, rheumatic and autoimmune diseases, AIDS, rejection of transplanted organs and tissues (cf. below), rhinitis, chronic obstructive pulmonary diseases, ulcerative colitis, sinusitis, lupus erythematosus, recurrent infections, atopic dermatitis/eczema and occupational allergies, food allergies, drug allergies, severe anaphylactic reactions, anaphylaxis, and other manifestations of allergic disease, as well as uncommon problems such as primary immunodeficiencies, including antibody deficiency states, cell mediated immunodeficiencies (e.g., severe combined immunodeficiency, DiGeorge syndrome, Hyper-IgE syndrome, Wiskott-Aldrich syndrome, ataxia-telangiectasia), immune mediated cancers, and white cell defects.
“Autoimmune disease” refers to a category of more than 80 chronic illnesses, each very different in nature, that can affect everything from the endocrine glands (like the thyroid) to organs like the kidneys, as well as to the digestive system.
In autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis (RA), multiple sclerosis (MS), immune-mediated or type 1 diabetes mellitus, immune mediated glomerulonephritis, scleroderma, pernicious anemia, alopecia, pemphigus, pemphigus vulgaris, myasthenia gravis, inflammatory bowel diseases, Crohn's disease, psoriasis, autoimmune thyroid diseases, and Hashimoto's disease, Hashimoto's thyroiditis, dermatomyositis, goodpasture syndrome, myasthenia gravis pseudoparalytica, ophtalmia sympatica, phakogene uveitis, chronical aggressive hepatitis, primary billiary cirrhosis, autoimmune hemolytic anemy, Werlof disease, specific cells uncontrollably attack the body's own tissues and organs (autoimmunity), producing inflammatory reactions and other serious symptoms and diseases.
There are many different autoimmune diseases, and they can each affect the body in different ways. For example, the autoimmune reaction is directed against the brain in multiple sclerosis and the gut in Crohn's disease. In other autoimmune diseases such as systemic lupus erythematosus (lupus), affected tissues and organs may vary among individuals with the same disease. One person with lupus may have affected skin and joints whereas another may have affected skin, kidney, and lungs. Ultimately, damage to certain tissues by the immune system may be permanent, as with destruction of insulin-producing cells of the pancreas in Type 1 diabetes mellitus.
Another aspect of the present invention is directed to the use of at least one compound of the general formula (I) and/or pharmaceutically acceptable salts thereof for prophylaxis and/or treatment of bipolar and clinical disorders.
The term “bipolar and clinical disorders” shall refer to adjustment disorders, anxiety disorders, delirium, dementia, amnestic and other cognitive disorders, disorders usually first diagnosed in infancy (e.g.), childhood, or adolescence, dissociative disorders (e.g. dissociative amnesia, depersonalization disorder, dissociative fugue and dissociative identity disorder), eating disorders, factitious disorders, impulse-control disorders, mental disorders due to a general medical condition, mood disorders, other conditions that may be a focus of clinical attention, personality disorders, schizophrenia and other psychotic disorders, sexual and gender identity disorders, sleep disorders, somatoform disorders, substance-related disorders, generalized anxiety disorder (e.g. acute stress disorder, posttraumatic stress disorder), panic disorder, phobia, agoraphobia, obsessive-compulsive disorder, stress, acute stress disorder, anxiety neurosis, nervousness, phobia, posttraumatic stress disorder, posttraumatic stress disorder (PTSD), abuse, obsessive-compulsive disorder (OCD), manic depressive psychosis, specific phobias, social phobia, adjustment disorder with anxious features.
Examples for disorders usually first diagnosed in infancy, childhood, or adolescence are: mental retardation, learning disorders, mathematics disorder, reading disorder, disorder of written expression, motor skills disorders, developmental coordination disorder, communication disorders, expressive language disorder, phonological disorder, mixed receptive-expressive language disorder, stuttering, pervasive developmental disorders, Asperger's disorder, autistic disorder, childhood disintegrative disorder, Rett's disorder, pervasive developmental disorder, attention-deficit/hyperactivity disorder (ADHD), conduct disorder, oppositional defiant disorder, feeding disorder of infancy or early childhood, pica, rumination disorder, tic disorders, chronic motor or vocal tic disorder, Tourette's syndrome, elimination disorders, encopresis, enuresis, selective mutism, separation anxiety disorder, reactive attachment disorder of infancy or early childhood, stereotypic movement disorder.
Examples for substance-related disorders are: alcohol related disorders, amphetamine related disorders, caffeine related disorders, cannabis related disorders, cocaine related disorders, hallucinogen related disorders, inhalant related disorders, nicotine related disorders, opioid related disorders, psychotic disorder, psychotic disorder, phencyclidine-related disorder, abuse, persisting amnestic disorder, anxiety disorder, persisting dementia, dependence, intoxication, intoxication delirium, mood disorder, psychotic disorder, withdrawal, withdrawal delirium, sexual dysfunction, sleep disorder.
The inventive compounds are also useful for prophylaxis and/or treatment of cardiovascular diseases such as adult congenital heart disease, aneurysm, stable angina, unstable angina, angina pectoris, angioneurotic edema, aortic valve stenosis, aortic aneurysm, arrhythmia, arrhythmogenic right ventricular dysplasia, arteriosclerosis, arteriovenous malformations, atrial fibrillation, Behcet syndrome, bradycardia, cardiac tamponade, cardiomegaly, congestive cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, cardiovascular disease prevention, carotid stenosis, cerebral hemorrhage, Churg-Strauss syndrome, diabetes, insulin resistance and diabetes including non-insulin-dependent diabetes mellitus (NIDDM), Ebstein's Anomaly, Eisenmenger complex, cholesterol embolism, bacterial endocarditis, fibromuscular dysplasia, congenital heart defects, heart diseases, congestive heart failure, heart valve diseases, heart attack, epidural hematoma, hematoma, subdural, Hippel-Lindau disease, hyperemia, hypertension, pulmonary hypertension, hypertrophic growth, left ventricular hypertrophy, right ventricular hypertrophy, hypoplastic left heart syndrome, hypotension, intermittent claudication, ischemic heart disease, Klippel-Trenaunay-Weber syndrome, lateral medullary syndrome, long QT syndrome mitral valve prolapse, moyamoya disease, mucocutaneous lymph node syndrome, myocardial infarction, myocardial ischemia, myocarditis, pericarditis, peripheral vascular diseases, phlebitis, polyarteritis nodosa, pulmonary atresia, Raynaud disease, chronic renal failure, restenosis, Sneddon syndrome, stenosis, superior vena cava syndrome, syndrome X, tachycardia, Takayasu's arteritis, hereditary hemorrhagic telangiectasia, telangiectasis, temporal arteritis, tetralogy of fallot, thromboangiitis obliterans, thrombosis, thromboembolism, tricuspid atresia, varicose veins, vascular diseases, vasculitis, vasospasm, ventricular fibrillation, Williams syndrome, peripheral vascular disease, varicose veins and leg ulcers, deep vein thrombosis, Wolff-Parkinson-White syndrome.
Preferred are adult congenital heart disease, aneurysms, angina, angina pectoris, arrhythmias, cardiovascular disease prevention, cardiomyopathies, congestive heart failure, myocardial infarction, pulmonary hypertension, hypertrophic growth, restenosis, stenosis, thrombosis and arteriosclerosis.
In yet another preferred embodiment, the cell proliferative disease is cancer, which is preferably selected from the group comprising:
The proliferation disorders and cancers are preferably selected from the group comprising advanced cancers, lymphoid malignancies and tumor metastases, especially adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, desmoid tumor, bladder cancer, bronchial carcinoma, breast cancer, Burkitt's lymphoma, corpus cancer, CUP-syndrome (carcinoma of unknown primary), colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors, gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, cervix, glioblastomas, gynecologic tumors, ear, nose and throat tumors, hematologic neoplasias, hairy cell leukemia, urethral cancer, skin cancer, skin testis cancer, brain tumors (gliomas), brain metastases, testicle cancer, hypophysis tumor, carcinoids, Kaposi's sarcoma, laryngeal cancer, germ cell tumor, bone cancer, colorectal carcinoma, head and neck tumors (tumors of the ear, nose and throat area), colon carcinoma, craniopharyngiomas, oral cancer (cancer in the mouth area and on lips), cancer of the central nervous system, liver cancer, liver metastases, leukemia, eyelid tumor, lung cancer, lymph node cancer (Hodgkin's/Non-Hodgkin's), lymphomas, stomach cancer, malignant melanoma, malignant neoplasia, malignant tumors gastrointestinal tract, breast carcinoma, rectal cancer, medulloblastomas, melanoma, meningiomas, Hodgkin's disease, mycosis fungoides, nasal cancer, neurinoma, neuroblastoma, kidney cancer, renal cell carcinomas, non-Hodgkin's lymphomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcomas, ovarial carcinoma, pancreatic carcinoma, penile cancer, plasmocytoma, prostate cancer, pharyngeal cancer, rectal carcinoma, retinoblastoma, vaginal cancer, thyroid carcinoma, Schneeberger disease, esophageal cancer, spinalioms, T-cell lymphoma (mycosis fungoides), thymoma, tube carcinoma, eye tumors, urethral cancer, urologic tumors, urothelial carcinoma, vulva cancer, wart appearance, soft tissue tumors, soft tissue sarcoma, Wiim's tumor, cervical carcinoma and tongue cancer.
Preferred are the following cancer types: bladder, breast, central nervous system, colon, gastric, lung, kidney, melanoma, head and neck, ovarian, cervix, glioblastoma, pancreas, prostate, stomach, skin testis, leukemia, Hodgkin's lymphoma, liver and renal cancer.
In yet another preferred embodiment, said diabetes is selected from Type I diabetes or Type II diabetes and non-insulin-dependent diabetes mellitus (NIDDM).
In yet another preferred embodiment, said inflammation is mediated preferably by the cytokines TNF-α, IL-1β, GM-CSF, IL-6 and/or IL-8.
As described above, the compounds according to general formula (I) are pharmaceutically active agents for prophylaxis and/or treatment of inflammatory diseases. Thus, these compounds are used for the manufacture of a pharmaceutical formulation for prophylaxis and/or treatment of inflammations and inflammatory diseases in mammals, including humans.
Inflammatory diseases can emanate from infectious and non-infectious inflammatory conditions which may result from infection by an invading organism or from irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic causes as shown in the following list.
I. Acute infections
Thus, the compounds disclosed herein can be used for prophylaxis and/or treatment of inflammations caused by invading organisms such as viruses, bacteria, prions, and parasites as well as for prophylaxis and/or treatment of inflammations caused by irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic reasons.
Consequently, the disclosed compounds are useful for prophylaxis and/or treatment of inflammatory diseases which are initiated or caused by viruses, parasites, and bacteria which are connected to or involved in inflammations.
The following bacteria are known to cause inflammatory diseases: mycoplasma pulmonis (causes e.g. chronic lung diseases (CLD), murine chronic respiratory disease), ureaplasma urealyticum (causes pneumonia in newborns), mycoplasma pneumoniae and chlamydia pneumoniae (cause chronic asthma), C. pneumoniae (causes atherosclerosis, pharyngitis to pneumonia with empyema, human coronary heart disease), Heliobacter pylori (human coronary heart disease, stomach ulcers).
The following viruses are known to cause inflammatory diseases: herpes viruses especially cytomegalovirus (causes human coronary heart disease).
The compounds disclosed herein are useful for prophylaxis and/or treatment of inflammatory diseases caused and/or induced and/or initiated and/or enhanced by the afore-mentioned bacteria or viruses.
Furthermore, the compounds of formula (I) are useful for prophylaxis and/or treatment of inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, inflammatory diseases of the larynx. Examples are osteoarthritis, septic arthritis, bone resorption, postmenopausal osteoperosis, sepsis, gram negative sepsis, septic shock, endotoxin shock, systemic inflammatory response syndrome, irritable bowel syndrome, Jarisch Heryheimer reactions, adult respiratory distress syndrome, acute pulmonary fibrotic diseases, pulmonary sarcoidosis, allergic respiratory diseases, COPD (chronic obstructive pulmonary disease), silicosis, coal worker's pneumoconiosis, alveolar injury, hepatic failure, liver disease during acute inflammation, immunedeficiency and fibrotic diseases, dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UV)-induced skin damage.
Examples for inflammatory diseases of the central nervous system (CNS) are algal disorders, protothecosis, bacterial disorders, abscessation, bacterial meningitis, idiopathic inflammatory disorders, eosinophilic meningoencephalitis, feline polioencephalomyelitis, granulomatous meningoencephalomyelitis, meningitis, steroid responsive meningitis-arteritis, miscellaneous meningitis/meningoencephalitis, necrotizing encephalitis, pyogranulomatous meningoencephalomyelitis, shaker dog disease, mycotic diseases of the CNS, parasitic encephalomyelitis, prion protein induced diseases, feline spongiform encephalopathy, protozoal encephalitis-encephalomyelitis, toxoplasmosis, neosporosis, sarcocystosis, encephalitozoonosis, trypanosomiasis, acanthamebiasis, babesiosis, leishmaniasis, rickettsial disorders, rocky mountain spotted fever, canine ehrlichiosis, viral disorders, aujeszky's disease, borna disease, canine herpes virus encephalomyelitis, canine distemper encephalomyelitis, canine distemper encephalomyelitis in immature animals, multifocal distemper encephalomyelitis in mature animals, old dog encephalitis, chronic relapsing encephalomyelitis, post-vaccinal canine distemper encephalitis, feline immunodeficiency virus, feline infectious peritonitis, feline leukemia virus, infectious canine hepatitis, La Crosse virus encephalitis, parvovirus encephalitis, rabies, post-vaccinal rabies, tick-borne encephalitis in dogs.
Examples for inflammatory rheumatic diseases are rheumatoid arthritis, scleroderma, lupus, polymyositis, dermatomyositis, psoriatic arthritis, ankylosing spondylitis, Reiters's syndrome, juvenile rheumatoid arthritis, bursitis, tendinitis (tendonitis), and fibromyositis.
Examples for inflammatory diseases of blood vessels are vasculitis, autoantibodies in vasculitis, microscopic polyangiitis, giant cell arteritis, Takayasu's arteritis, vasculitis of the central nervous system, thromboangiitis obliterans (Buerger's Disease), vasculitis secondary to bacterial, fungal, and parasitic infection, vasculitis and rheumatoid arthritis, vasculitis in systemic lupus erythematosus, vasculitis in the idiopathic inflammatory myopathies, relapsing polychondritis, systemic vasculitis in sarcoidosis, vasculitis and malignancy, and drug-induced vasculitis.
Examples for inflammatory diseases of the middle ear are acute suppurative otitis media, bullous myringitis, granular myringitis, and chronic suppurative otitis media, which can manifest as mucosal disease, cholesteatoma, or both.
Examples for inflammatory bowel diseases are ulcerative colitis, Crohn's disease.
Examples for inflammatory diseases of the skin are acute inflammatory dermatoses, urticaria (hives), spongiotic dermatitis, allergic contact dermatitis, irritant contact dermatitis, atopic dermatitis, erythemal multiforme (EM minor), Stevens-Johnson syndrome (SJS, EM major), toxic epidermal necrolysis (TEN), chronic inflammatory dermatoses, psoriasis, lichen planus, discoid lupus erythematosus, and acne vulgaris
Uveitis are inflammations located in and/or on the eye and may be associated with inflammation elsewhere in the body. In most circumstances, patients who have uveitis as part of a disease elsewhere in the body are aware of that illness. The majority of patients with uveitis do not have an apparent associated systemic illness. Causes of uveitis can be infectious causes, masquerade syndromes, suspected immune-mediated diseases, and/or syndromes confined primarily to the eye.
The following viruses are associated with inflammations: human immunodeficiency virus-I, herpes simplex virus, herpes zoster virus, and cytomegalovirus.
Bacterial or spirochetal caused, induced, initiated and/or enhanced inflammations are tuberculosis, leprosy, proprionobacterium, syphilis, Whipple's disease, leptospirosis, brucellosis, and lyme disease.
Parasitic (protozoan or helminthic) caused, induced, initiated and/or enhanced inflammations are toxoplasmosis, acanthameba, toxocariasis, cysticercosis, onchocerciasis.
Examples of inflammatory diseases caused, induced, initiated and/or enhanced by fungi are histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, sporotrichosis, blastomycosis, and cryptococcosis.
Masquerade syndromes are, for instance, leukemia, lymphoma, retinitis pigmentosa, and retinoblastoma.
Suspected immune-mediated diseases can be selected from the group comprising ankylosing spondylitis, Behcet's disease, Crohn's disease, drug or hypersensitivity reaction, interstitial nephritis, juvenile rheumatoid arthritis, Kawasaki's disease, multiple sclerosis, psoriatic arthritis, Reiter's syndrome, relapsing polychondritis, sarcoidosis, Sjogren's syndrome, systemic lupus erythematosus, ulcerative colitis, vasculitis, vitiligo, Vogt Koyanagi Harada syndrome.
Syndromes confined primarily to the eye are, for instance, acute multifocal placoid pigmentary epitheliopathy, acute retinal necrosis, birdshot choroidopathy, Fuch's heterochromic cyclitis, glaucomatocyclitic crisis, lens-induced uveitis, multifocal choroiditis, pars planitis, serpiginous choroiditis, sympathetic ophthalmia, and trauma.
Examples for inflammatory diseases of the larynx are gastroesophageal (laryngopharyngeal) reflux disease, pediatric laryngitis, acute laryngeal infections of adults, chronic (granulomatous) diseases, allergic, immune, and idiopathic disorders and miscellaneous inflammatory conditions.
Pediatric laryngitis is known as acute (viral or bacterial) infection such as laryngotracheitis (croup), supraglottis (epiglottitis), diphtheria, and noninfectious causes are for example spasmodic croup and traumatic laryngitis.
Acute laryngeal infections of adults are, for instance, viral laryngitis, common upper respiratory infection, laryngotracheitis, herpes simplex, bacterial laryngitis, supraglottis, laryngeal abscess, and gonorrhea.
Chronic (granulomatous) diseases can be selected from the group comprising bacterial diseases, tuberculosis, leprosy, scleroma, actinomycosis, tularemia, glanders, spirochetal (syphilis) diseases, mycotic (fungal) diseases, candidiasis, blastomycosis, histoplasmosis, coccidiomycosis, aspergillosis, idiopathic diseases, sarcoidosis, and Wegener's granulomatosis.
Allergic, immune, and idiopathic disorders are, for example, hypersensitivity reactions, angioedema, Stevens-Johnson syndrome, immune and idiopathic disorders, infections of the immunocompromised host, rheuatoid arthritis, systeic lupus erythematosus, cicatricial pemphigoid, relapsing polychondritis, Sjogren's syndrome, and amyloidosis.
Miscellaneous inflammatory conditions are, for instance, parasitic infections, trichinosis, leishmaniasis, schistosomiasis, syngamus laryngeus, inhalation laryngitis, acute (thermal) injury, pollution and inhalant allergy, carcinogens, radiation injury, radiation laryngitis, radionecrosis, vocal abuse, vocal-cord hemorrhage, muscle tension dysphonias, and contact ulcer and granuloma.
Transplant rejection is when a transplant recipient's immune system attacks a transplanted organ or tissue. No two people (except identical twins) have identical tissue antigens. Therefore, in the absence of immunosuppressive drugs, organ and tissue transplantation would almost always cause an immune response against the foreign tissue (rejection), which would result in destruction of the transplant. Though tissue typing ensures that the organ or tissue is as similar as possible to the tissues of the recipient, unless the donor is an identical twin, no match is perfect and the possibility of organ/tissue rejection remains.
The inventive compounds of general formula (I) are used as immunosuppressive drugs and/or anti-rejection drugs in order to prevent transplant rejection such as systemic lupus erythematosis, host-versus-graft reactions, ischemia reperfusion injury and allograft rejection including chronic lung, kidney and heart allograft rejection, complications due to total hip replacement, and ankylosing spondylitis.
One example of transplant rejection is the graft-versus-host-disease (GVHD) that can occur following bone marrow transplant. The donor's immune cells in the transplanted marrow make antibodies against the host's (transplant patient's) tissues and attack the patient's vital organs. Transplant rejections (also known as graft rejection or tissue/organ rejection) may commonly occur when tissue or organs, which need blood supply, are transplanted. Said organs comprise especially inner organs such as heart, heart-lungs, lungs, liver, kidney, pancreas, spleen, skin, tissue, bone marrow, spinal marrow, hormone producing glands, gonads and gonadal glands.
Another aspect of the present invention is directed to the use of at least one compound of the general formula (I) and/or pharmaceutically acceptable salts thereof for prophylaxis and/or treatment of neurodegeneration and neurodegenerative disorders.
Among the hundreds of different neurodegenerative disorders, the attention has been given only to a handful, including Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lateral sclerosis.
It is worth to mention that the same neurodegenerative process can affect different areas of the brain, making a given disease appear very different from a symptomatic standpoint.
Neurodegenerative disorders of the central nervous system (CNS) can be grouped into diseases of the cerebral cortex (Alzheimer disease), the basal ganglia (Parkinson disease), the brain-stem and cerebellum, or the spinal cord (amyotrophic lateral sclerosis).
Examples for neurodegeneration and neurodegenerative disorders are Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, AIDS-related dementia, retinitis pigmentosa, spinal muscular atrophy and cerebrellar degeneration, fragile X-associated tremor/ataxia syndrome (FXTAS), progressive supranuclear palsy (PSP), and striatonigral degeneration (SND), which is included with olivopontocerebellear degeneration (OPCD), and Shy Drager syndrome (SDS) in a syndrome known as multiple system atrophy (MSA), acute encephalitis, brain injury, amyotrophic lateral sclerosis and inflammatory pain, regenerative (recovery) treatment of CNS disorders such as spinal cord injury, acute neuronal injury (stroke, traumatic brain injury) progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic, pugilistic encephalitis, guam parkinsonism-dementia complex, corticobasal degeneration, frontotemporal dementia, AIDS associated dementia, mood disorders.
According to a still further aspect, the present invention refers to pharmaceutical compositions comprising at least one compound according to the present invention as an active ingredient together with at least one pharmaceutically acceptable (i.e. non-toxic) carrier, excipient and/or diluent. The pharmaceutical compositions of the present invention can be prepared in a conventional solid or liquid carrier or diluent and a conventional pharmaceutically-made adjuvant at suitable dosage level in a known way. The preferred preparations are adapted for oral application. These administration forms include, for example, pills, tablets, film tablets, coated tablets, capsules, micro- and nano formulations, liposomal formulations, powders and deposits.
Furthermore, the present invention also includes pharmaceutical preparations for parenteral application, including dermal, intradermal, intragastral, intracutan, intravasal, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutan, rectal, subcutaneous, sublingual, topical, or transdermal application, which preparations in addition to typical vehicles and/or diluents contain at least one compound according to the present invention and/or a pharmaceutical acceptable salt thereof as active ingredient.
The pharmaceutical compositions according to the present invention containing at least one compound according to the present invention and/or a pharmaceutical acceptable salt thereof as active ingredient will typically be administered together with suitable carrier materials selected with respect to the intended form of administration, i.e. for oral administration in the form of tablets, capsules (either solid filled, semi-solid filled or liquid filled), powders for constitution, gels, elixirs, dispersable granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices. For example, for oral administration in the form of tablets or capsules, the active drug component may be combined with any oral non-toxic pharmaceutically acceptable carrier, preferably with an inert carrier like lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid filled capsules) and the like. Moreover, suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated into the tablet or capsule. Powders and tablets may contain about 5 to about 95 weight % of the pyridinylamines and/or the respective pharmaceutically active salt as active ingredient.
Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. Among suitable lubricants there may be mentioned boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Suitable disintegrants include starch, methylcellulose, guar gum, and the like. Sweetening and flavoring agents as well as preservatives may also be included, where appropriate.
Moreover, the pharmaceutical compositions of the present invention may be formulated in sustained release form. Suitable dosage forms for sustained release include tablets having layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices. Liquid form preparations include solutions, suspensions, and emulsions. Liquid form preparations may also include solutions for intranasal administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be present in combination with a pharmaceutically acceptable carrier such as an inert, compressed gas, e.g. nitrogen.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides like cocoa butter is melted first, and the active ingredient is then dispersed homogeneously therein e.g. by stirring. The molten, homogeneous mixture is then poured into conveniently sized moulds, allowed to cool, and thereby solidified.
Under tablet a compressed or moulded solid dosage form is understood which comprises the active ingredients with suitable diluents. The tablet may be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation, or by compaction well known to a person of ordinary skill in the art.
Powders for constitution refers to powder blends containing the active ingredients and suitable diluents which can be suspended e.g. in water or in juice.
Another aspect of the present invention is directed to combination therapies wherein at least one compound according to any formula (I) to (III) is administered together with a known or commonly used drug against infectious diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke. Especially preferred are combination therapies including systemic combination therapies of at least one compound of the present invention together with known or commonly used HIV drugs, antibiotics or anticancer drugs. Furthermore, the inventive compounds can also be applied in addition to chemotherapy or any other radiotherapy such as hyperthermia for cancer treatment.
In order to determine the inhibitory effect of the compounds of the subject invention on various target enzymes a generic kinase assay was established.
Reactions were performed in 96-Well U-bottom microtiter plates (Greiner Bio-One; Frickenhausen/Germany, Cat. No. 650161), hereinafter designated “Assay Plates”. 10 μl of a solution comprising 40 μM Myelin Basic Protein (Invitrogen; Carlsbad, Calif./USA; Cat. No. 13228-010) and 4 μM ATP in three-fold concentrated Reaction Buffer (60 mM Tris-HCl, pH 7.5; 30 mM MgCl2; 3 mM dithiothreitol) were added into each well of the Assay Plate. 10 μl of serial dilutions of the compounds of the subject invention, dissolved in 4% DMSO, were then added into each well, except for Positive Control. Wells (C+ wells) and Negative Control Wells (C− wells). 10 μl of 4% DMSO without compounds were added to C+ and C− wells. 10 μl of a 500 mM solution of EDTA in water was then added to C− wells. Then 10 μl of a solution containing 50 μCi/ml Adenosine 5′-[γ-33P]triphosphate in water was added to each well. To start the reaction 10 μl of the kinase to be assayed was added to each well. The optimal amount of kinase in the assay was determined to be the amount which yields to a turn-over of about 10% of ATP. Assay Plates were incubated for one hour at room temperature. Then 10 μl of a 500 mM solution of EDTA in water was added to each well except C− wells. Samples were now ready for measurement.
Measurements were preformed in 96-Well MAPH-Filter Plates (Millipore; Billerica, Mass./United States; Cat. No. MAPHNOB50), hereinafter designated “Measurement Plates”. Measurement Plates were washed with 200 μl of a 0.75% H3PO4 solution per well. The H3PO4 solution was exhausted using a Millipore vacuum station. 60 μl of a 0.75% H3PO4 solution was then added into each well, followed by the transfer of 30 μl of each well from the Assay Plate into the corresponding wells of the Measurement Plate. The Measurement Plate was incubated for 30 minutes at room temperature. Thereafter each well was washed three times with 200 μl of a 0.75% H3PO4 solution using a Millipore vacuum station. 20 μl of scintillation liquid (Supermix Liquid Szintillator; Perkin Elmer, Wellesley. Mass./United States; Cat. No. 1200-439) was then added to each well of the Measurement Plate. The plate was sealed and stored for 30 minutes in the darkness before radioactivity was quantified in a MicroBeta Scintillation Counter (Perkin Elmer, Wellesley. Mass./United States).
The following Table 2a shows the inhibitory effect of representative compounds of the present invention on various target enzymes.
Target cRaf
Target c-kit
Target Abl
Target RICK
Target CDK1/CyclinB
We observed the surprising finding that compounds of the present invention were useful in inhibiting or killing a large variety of tumor cells. Tumor cell lines tested included:
Cells were exposed to the test compounds at various concentration in 384 well plates. Experiments were performed in triplicates. The following cell numbers were plated in the respective media (see above) in a volume of 25 μl: cell lines A2780 and A549 at 200 cells per well, cell line B 16-F1 at 250 cells per well and cell line HT-29 at 100 cells per well. Cell were incubated for 24 hours at 37° C. and 7% CO2 before the compounds of the subject invention, i.e. the test compounds, were added to yield final concentrations of 30, 10, 3.3, 1.1, 0.37 and 0.12 μM. Test Compounds were added from 30O× concentrated stock solutions in DMSO. Plates were then incubated for 72 hours at the conditions described above. Then 5 μl of a alamar blue solution (Biozol, Eching/Germany, Cat. No. BZL 00727) was added and the plates were incubated for 4 hours at the conditions described above. Then fluorescence was measured at an optical density of 560/590 nm (excitation at 560 nm, emission at 590 nm) in a Wallac Victor2 multilabel counter (Perkin Elmer, Wellesley. Mass./United States). Inhibitory activity of the compounds was calculated as % inhibition compared to cells treated with DMSO (negative control). As a positive control cells were treated with doxurubicin (final concentrations of doxorubicin: 1 μM, 0.3 μM and 0.1 μM; experimental set up and dilutions for the positive and the negative control were identical to the wells treated with test compounds).
Table 2b shows the level of inhibition of four tumor cell lines after incubation with compounds of the present invention. All compounds demonstrated a clear and pronounced anti-proliferative activity towards a this panel of cancer cell lines. This surprising effect over various different cancer cell lines indicates that the subject compounds have strong anti-cancer activity.
Clonogenic Survival Assay with HCT-116 Cells.
With this assay we determine the concentration of a compound which leads to the irreversible loss of viability after a specified period of exposure. All steps are performed using aseptic techniques.
Compounds of the present invention lead to an irreversible loss of viability of HCT-116 cells after 24 hours of exposure to the compounds of the present invention. Said compounds not only lead to an growth arrest, but cause an irreversible loss of viability.
With this assay we demonstrate in-vivo activity of compounds of the present invention.
Mice are obtained from Charles River, housed in static microisolators, and provided ad libitum with water and an irradiated standard rodent diet (Purina Pico-Lab Rodent Diet 20).
Mice at 8 weeks of age are pair-matched into groups of 5-8 animals and preliminary toxicity studies are performed with unknown test compounds. Animals are treated i.v. daily for 10 consecutive days with test compound and are weighed twice weekly. Mice are examined frequently for clinical signs of any adverse drug-related effects. Acceptable toxicity for anti-cancer drugs in mice is defined by the NCI as no mean group weight loss of over 20% and not more than 10% toxic death in treated animals.
Athymic nude mice (male or female, 6-7 weeks; athymic nude mice are hairless, lack a normal thymus gland, and have a defective immune system because of a genetic mutation) are implanted s.c. with single 1 mm3 tumor fragments (tumor brie) or alternatively, 5-10×106 tissue culture-derived cells into the flank. Animals are initially monitored twice weekly for tumor growth and then daily as the implants approach the desired size of approximately 100 mm3. When the tumors grow to between 50-250 mg in calculated tumor weight, the animals are pair-matched into appropriate experimental treatment groups (8-10 animals/group) and treatment with test compounds is initiated. A positive control is dosed according to historical controls. Tumor weights are calculated and body weights are taken twice weekly and animals are observed frequently for adverse drug effects. The protocol calls for any animal whose tumor mass reaches 1,000 mg to be immediately euthanized.
Tumors are measured by determining the length and width of the tumor with a digital caliper. Tumor weight is estimated using the following formula:
Tumor Weight (mg)=(w2×l)/2
where w=width and l=length in mm of the tumor. These values can also be expressed in volumetric units (mm3).
Experimental treatment may cause partial regression (PR) or complete regression (CR) of tumors. PR is where the tumor size is 50% or less of the starting (day 1) size but greater than 0.0 mg for three consecutive days during the course of the study, whereas a CR occurs when there is no measurable tumor mass for three consecutive days. Cures are defined as animals whose tumor shrinks to 0 mg and remains that way until the completion of the experiment.
Log cell kill (LCK) is a calculation that determines the percentage of tumor cells that are killed after the initiation of treatment and can be used as a quantitative measure of efficacy:
Log Cell Kill (LCK)=(T−C)/(3.32)(Td)
where T=is the mean time required for the treatment group of mice to reach 1,000 mg in size, C=the mean time for the control group tumors to reach 1,000 mg in size, Td=is the tumor doubling time estimated from the linear regression analysis from a semi-log growth plot of the control group tumors during exponential growth and 3.32=the number of doublings required for a population to increase 1-log 10 unit. Each LCK unit represents 1-log 10 unit of cell killing (e.g. 1 LCK=90% kill, 2 LCK=99% kill, etc.). We consider compounds to be significantly active when they have LCK values >1, which corresponds to >90% tumor cell kill.
Tumor growth inhibition (TGI) is a calculation that describes the amount of tumor growth that is inhibited by treatment with a compound over a defined period of time. It is expressed as:
% TGI=100(1−T/C)
where T is the mean tumor size of a compound treated group on a given day, and C is the mean tumor size of the vehicle control group on the same day.
Toxic deaths are defined as deaths caused by compound treatment and not by advanced disease state. A death is considered toxic if the animal dies within 1 week after the final compound treatment and the tumor size has not reached 1,000 mg. Non-tumor related deaths after this point are recorded, but not considered toxic deaths.
Tumor regression is defined according the following conventions: a regression is defined as partial (PR) if the tumor weight decreases to <50% of the starting weight (<50 mg). A regression is defined as complete (CR) if the tumor weight decreases below measurable weight during the experimental period. A cure is defined as a tumor-free animal at end of the observation period.
Similarly, experiments are performed in a syngeneic ip/ip mouse model.
Results. Compounds of the present invention show the following effects in the describe xenograft mouse model: (1) weight and size of tumors are smaller for compound treated animals as compared to the control groups, (2) Log cell kill (LCK) is higher for compound treated animals as compared to the control groups, and (3) Tumor growth inhibition (TGI) is higher for compound treated animals as compared to the control groups.
In order to select the most appropriate compound to enter further experiments and to assess its suitability for use in a therapeutic composition for the treatment of disorders and diseases, such as cancers, additional data are collected. Such data can include the in vitro killing efficiency as measured by IC50 and cytotoxicity across a panel of tumor cell lines, the percentage cell killing as estimated in vitro, and tumor reduction data and mouse survival data from in vivo animal models. Furthermore, such experiments may also include the elucidation and/or determination of the mechanism of action of the subject compound, the target of the subject compound, and other characteristics of the subject compound, such as the binding affinity of the compound to the target or the binding site of the compound on the target. Such experiments may also include molecular modelling of the drug-target interaction.
The compound that shows the lowest IC50 for killing, the highest percentage cell killing and broadest across various tumor cell lines, the best tumor reduction data and/or the best mouse-survival data may be chosen to enter further experiments. Such experiments may include, for example, therapeutic profiling and toxicology in animals, phase I clinical trials in humans and other clinical trails.
In the following section, general procedures are described for the synthesis of the compounds of the present invention.
The pyridinylamines of the present invention can be synthesized by the conversion of 3-amino-5-bromo pyridine with suitable aldehydes in the presence of sodium triacetoxyborohydride. In a subsequent reaction step the intermediate compound is reacted in a Suzuki like coupling reaction with a suitable aryl boronic acid or alkyl boronic acid or ester in order to obtain a compound according to general formula (I). The secondary amino residue can be converted to a tertiary amino residue by deprotonation with a suitable base such as sodium hydride or butyl lithium and subsequent reaction with an alkylating agent such as alkyl iodides or alkyl bromides. It is also possible to carry out the alkylating step before the Suzuki like coupling reaction. In this case, step 2 and step 3 are replaced with each other as indicated by the backslash arrow.
Another general method for the synthesis of the inventive compounds comprises the conversion of 3-amino-5-bromo pyridine with suitably substituted aryl boronic acids or alkyl boronic acids. Thereafter, the intermediate product is reacted in a Suzuki like coupling reaction with a second aryl boronic acid or alkyl boronic acid or ester in order to give compounds of the general formula (I).
The invention will now be illustrated by a series of examples which are intended to set forth typical and preferred procedures to be utilized in practice, but which shall not limit the ambit of the claims and the scope of protection.
In a first step according to scheme 3 and 4, a suitable carboxylic acid was reacted with 3-amino-5-bromo pyridine under formation of an amid bond in order to result in an intermediate product which was converted in a second step with an aryl boronic acid or alkyl boronic acid or ester in a Suzuki like coupling reaction. Compounds of general formula (I) were obtained having an amid residue which could in a third step be reduced to a methylene group be means of a suitable reducing agent such as boranes.
The Suzuki like coupling reaction is not limited to aryl boronic acids. It can also be carried out with heteroaryl boronic acids, phenetyl boronic acids, alkinyl boronic acids, or alkenyl boronic acids. Thus, the group R1 can be introduced by means of said Suzuki like coupling reaction as outlined in the following scheme 5.
The following compounds can be prepared according to scheme 1 and/or 3:
1-5, 11-15, 19-22, 25, 27-35, 39-42, 48-51, 57, 59, 70-72, 74-76, 79, 82, 87-92, 95-98, 102, 106-113, 116, 123-128, 130, 134, 135, 139, 141, 145, 154, 155, 159, 160, 163, 172, 176, 177, 181, 195, 202, 206, 207, 209, 212, 214-218, 221-226, 228-234, 236, 238, 239, 241-243, 245-249, 251, 254, 255, 257-259, 261-273.
The following compounds can be prepared according to scheme 2:
6-10, 16-18, 23, 24, 26, 36-38, 43-47, 52-56, 58, 60-69, 73, 77, 78, 80, 81, 83-86, 93, 94, 99-101, 103-105, 114, 115, 117-122, 129, 131-133, 136-138, 140, 142-144, 146-153, 156-158, 161, 162, 164-171, 173-175, 178-180, 182-194, 196-201, 203-205, 208, 210, 211, 213, 219, 220, 227, 235, 237, 240, 250, 252, 274.
The following compounds can be prepared according to scheme 4:
224, 256.
LC/MS data were obtained using a Micromass ZQ instrument with atmospheric pressure chemical ionisation or electrospray ionisation under the conditions described below.
Purity is assessed as the integral over the window 210-400 nm.
If necessary, specific wavelength traces are extracted from the DAD data. Optional ELS detection was conducted using Polymer Labs ELS-1000.
MS Detection: Either Micromass Platform or ZQ, both Single Quadrapole LC-MS Instruments.
Scan range for MS Data (m/z)
Start (m/z) 100
End (m/z) 650
With +ve/−ve switching
Ionisation is either electrospray or APCI dependent on compound types.
Purity is assessed as the integral over the window 210-400 nm.
If necessary, specific wavelength traces are extracted from the DAD data. Optional ELS detection was conducted using Polymer Labs ELS-1000.
MS Detection: Either Micromass Platform or ZQ, both Single Quadrapole LC-MS Instruments.
Scan range for MS Data (m/z)
Start (m/z) 100
End (m/z) 650
With +ve/−ve switching
Ionisation is either electrospray or APCI dependent on compound types.
All reagents were obtained commercially and used directly. DMF and THF were dried over 4A molecular sieves (Fisher Scientific). Column chromatography employed Silica Gel 60 (Fluka). TLC was carried out using pre-coated plastic sheets Polygram SIL G/UV254 (Macherey-Nagel).
The conditions for the standard basic LC-MS conditions for Method C1 are the same as for Method A1, with the distinction that for method C1 no buffer like ammonium bicarbonate (ammonium hydrogen carbonate) or formic acid was used.
Sodium triacetoxyborohydride (1.03 g, 4.87 mmol) was added to a mixture of 3-hydroxy benzaldehyde (425 mg, 3.48 mmol) and 3-amino-5-bromo pyridine (600 mg, 3.48 mmol) in DCM (10 ml). The reaction was stirred at room temperature for 18 hours. Reaction diluted with DCM (30 ml) and washed with de-ionised water (2×20 ml). Aqueous combined and extracted with EtOAc (3×30 ml). Organics combined, dried over MgSO4, filtered and evaporated to dryness. Residue triturated in petroleum ether 40/60 to give product (248) in 48% yield.
LC-MS, m/z [MH]+ 279. Retention time, 1.06 minutes. Method A.
1H NMR (DMSO-cfe, 400 MHz): δ=4.40 (d, 2H, CH2), 6.81 (d, 1H, Ar—H), 6.96 (m, 3H, Ar—H N—H)1 7.23 (d, 1H, Ar—H), 7.30 (t, 1H, Ar—H), 7.98 (s, 1H, Ar—H), 8.13 (s, 1H1Ar—H), 9.54 (s, 1H1OH).
To a solution of 3-[(5-bromo-pyridin-3-ylamino)-methyl]-phenol (248) (204 mg, 0.74 mmol) in de-gassed DMF (5 ml) under a N2 atmosphere, 2-fluoro-3-methoxyphenyl boronic acid (250 mg, 1.47 mmol), NaHCO3 (247 mg, 2.94 mmol), de-gassed de-ionised water (2 ml), triphenylphosphine (30 mg, O.Hmmol) and palladium acetate (9 mg, 0.07 mmol) were added. Reaction stirred at 80° C. for 18 hours. Reaction cooled and evaporated to dryness. Residue dissolved in EtOAc (40 ml) and washed with Na2CO3 (30 ml) and de-ionised water (30 ml), dried over MgSO4, filtered and evaporated to dryness. Residue triturated in DCM to give product (236) in 52% yield.
LC-MS, m/z [MH]+ 325. Retention time, 1.82 minutes. Method B.
1H NMR (DMSO-cfe, 400 MHz): δ=3.91 (s, 3H, CH3), 4.30 (d, 2H, CH2), 6.69-7.28 (9H, Ar—H, N—H), 7.90 (s, 1H, Ar—H), 8.05 (s, 1H, Ar—H), 9.38 (s, 1H, OH).
The following analogues of 3-{[5-(2-fluoro-3-methoxy-phenyl)-pyridin-3-ylamino]-methyl}-phenol (236), were prepared using the experimental procedures described above.
Furthermore, the following analogues are prepared using the same experimental procedures:
The following analogue is prepared as well using the same experimental procedure:
(compound 294)
The following derivatisations/transformations were also conducted:
To a solution of 3-{[5-(2-Fluoro-3-methoxy-phenyl)-pyridin-3-ylamino]-methyl}-phenol (236) (97 mg, 0.30 mmol) in DCM (15 ml) at −78° C. under a N2 atmosphere, a 1M solution of borontribromide in DCM (6 ml, 5.99 mmol) was added. Reaction was allowed to warm to room temperature and stirred for 18 hours. Reaction was quenched with addition of de-ionised water and pH adjusted to 6 by addition of 2M NaOH. Mixture was extracted with EtOAc (2×40 ml). The organic phases were combined, dried over MgSO4 and evaporated to dryness. Residue was purified by Prep-HPLC. Compound 231 was isolated in 37% yield.
LC-MS, m/z [MH]+ 311. Retention time, 1.44 minutes. Method B.
1H NMR (DMSO-de, 400 MHz): δ=4.38 (d, 2H, CH2), 6.72-7.25 (9H, Ar—H, N—H), 8.00 (s, 1H, Ar—H), 8.10 (s, 1H, Ar—H), 9.8 (br s, 2H, 2(OH)).
To a solution of 3-{[5-(3-hydroxy-phenyl)-pyridin-3-ylamino]methyl}-benzoic acid methyl ester (262) (53 mg, 0.16 mmol) in THF (2 ml) and de-ionised water (2 ml), lithium hydroxide. H2O (33 mg, 0.60 mmol) was added. Reaction was stirred for 18 hours at room temperature.
THF was evaporated and aqueous phase acidified to pH 3-4 with acetic acid then extracted with EtOAc (4×40 ml). The organic phases were combined, dried over MgSO4, filtered and evaporated. Residue was triturated in de-ionised water. Compound 263 could be isolated in 63% yield.
LC-MS, m/z [MH]+ 321. Retention time, 1.03 minutes. Method B.
1H NMR (DMSO-CZ6, 400 MHz): δ=4.62 (d, 2H, CH2), 6.86 (t, 1H, N—H), 6.95 (d, 1H, Ar—H)1 7.10 (s, 1H, Ar—H), 7.15 (d, 1H, Ar—H), 7.22 (s, 1H, Ar—H), 7.40 (t, 1H, Ar—H), 7.65 (t, 1H, Ar—H), 7.82 (d, 1H, Ar—H), 8.00 (d, 1H, Ar—H), 8.18 (m, 3H, Ar—H), 9.72 (br s, 1H, OH) 13.10 (br s, 1H, COOH).
A mixture of 264 3-{[5-(3-hydroxy-phenyl)-pyridin-3-ylamino]methyl}-benzoic acid methyl ester (63 mg, 0.19 mmol) in 35% Aq.ammonia (10 ml) was heated for 7 hours under reflux. Reaction was cooled and partitioned between EtOAc (30 ml) and de-ionised water (30 ml). Layers were separated and aqueous phase extracted with EtOAc (30 ml). The organic phases were combined, washed with brine (30 ml) dried over MgSO4, filtered and evaporated. Residue was purified by column chromatography. Mixture was pre absorbed onto flash silica and eluted with 10% MeOH/DCM. Compound 265 was isolated in 40% yield.
LC-MS, m/z [MH]+ 320. Retention time, 1.32 minutes. Method B.
1H NMR (DMSO-c/e, 400 MHz): δ=4.30 (d, 2H, CH2), 6.51 (t, 1H, N—H), 6.65-7.83 (13H, Ar—H, N—H) 9.40 (s, 1H, OH).
To a solution of 3-[5-(3-hydroxy-benzylamino)-pyridin-3-yl]-benzoic acid methyl ester (243) (83 mg, 0.25 mmol) in THF (2 ml) and de-ionised water (2 ml), lithium hydroxide. H2O (52 mg, 1.25 mmol) was added. Reaction was stirred for 8 hours at room temperature.
THF was evaporated and reaction mixture was acidified to pH 4-5 with acetic acid. Precipitate was collected by filtration, washing with diethyl ether (50 ml).
Compound 246 was isolated in 46% yield.
LC-MS, m/z [MH]+ 321. Retention time, 0.97 minutes. Method B.
1H NMR (DMSO-c/e, 400 MHz): δ=4.55 (d, 2H, CH2), 6.88 (d, 2H, Ar—H), 7.20-7.38 (4H, Ar—H, N—H), 7.85 (t, 1H, Ar—H), 8.10 (d, 1H, Ar—H), 8.20 (d, 1H, Ar—H), 8.26 (s, 1H, Ar—H), 8.30 (s, 1H, Ar—H), 8.36 (s, 1H, Ar—H), 9.60 (br s, 1H, OH), 13.35 (br s, 1H1COOH).
A solution of 3-[5-(3-nitro-benzylamino)-pyridin-3-yl]-phenol (266) (113 mg, 0.35 mmol) was hydrogenated over 10% Pd/C (20 mg) in a H2 atmosphere for 48 hours. Reaction was filtered through celite and evaporated to dryness. Residue was purified by column chromatography. Mixture was pre absorbed onto flash silica and eluted with 5% sat NH3 in MeOH/DCM. Compound 245 was isolated in 45% yield.
LC-MS, m/z[MH]+ 192. Retention time, 1.44 minutes. Method B.
1H NMR (DMSO-CZ6, 400 MHz): δ=4.10 (d, 2H, CH2), 4.98 (s, 2H, NH2), 6.30 (d, 1H, Ar—H), 6.40-6.90 (9H, Ar—H, N—H), 7.15 (t, 1H, Ar—H), 7.85 (d, 2H, Ar—H), 9.45 (s, 1H1O—H).
To a solution of 3-amino-5-bromo pyridine (300 mg, 1.74 mmol) in DCM (20 ml), phenyl boronic acid (424 mg, 3.48 mmol), pyridine (281 μl, 3.48 mmol), 4A mol sieves (200 mg) and copper(II) acetate (158 mg, 0.87 mmol) were added. Reaction was stirred for 18 hours under atmosphere.
Reaction was filtered, washing cake with MeOH and evaporated to dryness. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica, loaded onto a 10 g isolute flash Si cartridge and eluted using CombiFlash™ instrumentation, with a gradient of 0-60% EtOAc/petroleum ether 40/60 (v:v). (5-Bromo-pyridin-3-yl)-phenyl-amine was isolated in 29% yield.
LC-MS, m/z [MH]+ 249. Retention time, 1.84 minutes. Method A.
1H NMR (CDCl3, 400 MHz): δ=5.75 (br s, 1H, NH), 7.10 (m, 3H, Ar—H), 7.35 (m, 2H, Ar—H), 7.55 (s, 1H, Ar—H), 8.20 (s, 1H, Ar—H), 8.25 (s, 1H, Ar—H).
To a solution of (5-bromo-pyridin-3-yl)-phenyl-amine (120 mg, 0.48 mmol) in de-gassed DMF (5 ml) under a N2 atmosphere, 3-acetamidophenylboronic acid (173 mg, 0.97 mmol), NaHCO3 (162 mg, 1.93 mmol), de-gassed de-ionised water (2 ml), triphenylphosphine (19 mg, 0.071 mmol) and palladium acetate (5 mg, 0.024 mmol) were added. Reaction was stirred at 80° C. for 18 hours. Reaction was cooled and evaporated to dryness. Residue was dissolved in EtOAc (40 ml) and washed with de-ionised water (30 ml), dried over MgSO4, filtered and evaporated to dryness. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica and eluted with 5% MeOH/DCM. Compound 194 was isolated in 37% yield.
LC-MS, m/z [MH]+ 304. Retention time, 1.72 minutes. Method B.
1H NMR (DMSO-de, 400 MHz): δ=2.11 (s, 3H, CH3), 7.00 (t, 1H, Ar—H), 7.21 (d, 2H, Ar—H), 7.39-7.94 (7H, Ar—H, N—H), 8.32 (s, 1H, Ar—H), 8.41 (s, 1H, Ar—H), 8.60 (s, 1H, Ar—H), 10.11 (s, 1H, N—H).
The following analogues of N-[3-(5-phenylamino-pyridin-3-yl)-phenyl]-acetamide (194), were prepared using the experimental procedures described above.
#prepared using N-methyl aniline in preparation of analogue
To a solution of 3-amino-5-bromopyridine (150 mg, 0.87 mmol) in de-gassed DMF (5 ml) under a N2 atmosphere, 3-hydroxyphenyl boronic acid (240 mg, 1.75 mmol), NaHCO3 (293 mg, 3.5 mmol), de-gassed de-ionised water (2 ml), triphenylphosphine (34 mg, 0.131 mmol) and palladium acetate (10 mg, 0.436 mmol) were added. Reaction was stirred at 80° C. for 18 hours, then cooled and evaporated to dryness. Residue was dissolved in EtOAc (40 ml) and washed with de-ionised water (30 ml), dried over MgSO4, filtered and evaporated to dryness. Residue was triturated in ether to afford product. Compound was isolated in 63% yield.
LC-MS, m/z[MH]+ 187. Retention time, 1.08 minutes. Method B.
1H NMR (DMSO-CZ6, 400 MHz): δ=5.56 (br s, 2H, NH2), 6.94 (d, 1H, Ar—H), 7.10 (d, 1H, Ar—H), 7.15 (d, 1H, Ar—H) 7.21 (t, 1H, Ar—H), 7.40 (t, 1H Ar—H,), 8.05 (d, 1H, Ar—H), 8.10 (d, 1H, Ar—H), 9.73 (s, 1H, OH).
N-[3-(5-amino-pyridin-3-yl)phenyl]-acetamide (253) was prepared using the experimental procedure above. LC-MS, m/z [MH]+ 228. Retention time, 0.99 minutes. Method B.
To a solution of 3-(tert-butyl-dimethyl-silanyloxy)-benzoic acid (725 mg, 2.57 mmol) in DCM (25 ml) at room temperature, EDCI (1.28 g, 6.68 mmol) was added and reaction was stirred for 30 minutes. 3-Amino-5-bromopyridine (421 mg, 2.45 mmol) was then added and reaction was stirred at 30° C. for 24 hours. Reaction was cooled, diluted with DCM (30 ml) and washed with de-ionised water (30 ml), NaHCO3 (30 ml), de-ionised water (30 ml) and brine (30 ml)1 dried over MgSO4, filtered and evaporated. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica, loaded onto a 20 g isolute flash Si cartridge and eluted using CombiFlash™ instrumentation, with a gradient of 0-100% EtOAc/petroleum ether 40/60 (v:v). N-(5-Bromo-pyridin-3-yl)-3-(tert-butyl-dimethyl-silanyloxy)-benzamide was isolated in 30% yield.
LC-MS, m/z [MH]+ 407. Retention time, 2.95 minutes. Method B.
1H NMR (DMSO-de, 400 MHz): δ=0.27 (s, 6H, (CH3)2), 1-00 (s, 9H, (CH3)3), 7.15 (d, 1H, Ar—H), 7.42 (s, 1H, Ar—H) 7.50 (t, 1H, Ar—H) 7.62 (d, 1H, Ar—H) 8.48 (s, 1H, Ar—H), 8.52 (s, 1H, Ar—H), 8.95 (s, 1H, Ar—H), 10.51 (s, 1H, N—H).
To a solution of N-(5-bromo-pyridin-3-yl)-3-(tert-butyl-dimethyl-silanyloxy)-benzamide (290 mg, 0.71 mmol) in de-gassed DMF (5 ml) under a N2 atmosphere, 3-hydroxyphenyl boronic acid (197 mg, 1.43 mmol), NaHCO3 (240 mg, 2.85 mmol), de-gassed de-ionised water (2 ml), triphenylphosphine (28 mg, 0.107 mmol) and palladium acetate (8 mg, 0.036 mmol) were added. Reaction was stirred at 80° C. for 18 hours. Reaction was cooled and evaporated to dryness. Residue was dissolved in EtOAc (40 ml) and washed with de-ionised water (30 ml), dried over MgSO4, filtered and evaporated to dryness. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica and eluted with 5% MeOH/DCM. Product was triturated in diethyl ether. Compound 234 was isolated in 49% yield.
LC-MS, m/z [MH]+ 307. Retention time, 1.43 minutes. Method B.
1H NMR (DMSO-de, 400 MHz): δ=6.90 (d, 1H, Ar—H), 7.05 (d, 1H, Ar—H), 7.10 (s, 1H, Ar—H), 7.15 (d, 1H, Ar—H), 7.40 (m, 3H, Ar—H) 7.50 (d, 1H, Ar—H) 8.49 (s, 1H, Ar—H) 8.60 (s, 1H, Ar—H), 9.00 (s, 1H, Ar—H), 9.70 (s, 1H, O—H), 9.87 (s, 1H, O—H), 10.50 (s, 1H, N—H).
To a solution of [3-(tert-butyl-dimethyl-silanyoxy)-phenyl]acetic acid (1.70 g, 6.39 mmol) in THF (10 ml) and DMF (0.5 ml) at room temperature under a N2 atmosphere, Et3N (1.86 ml, 13.44 mmol) and 3-amino-5-bromo pyridine (1.15 g, 6.72 mmol) were added. Reaction was cooled to 0° C. and HBTU (2.55 g, 6.72 mmol), was added. Reaction was stirred at room temperature for 2 hours and then warmed to 50° C. and stirred for 18 hours. Reaction was cooled, diluted with EtOAc (30 ml) and washed with citric acid (30 ml), NaHCO3 (30 ml), de-ionised water (30 ml) and brine (30 ml), dried over MgSO4, filtered and evaporated. Residue was purified by flash chromatography. Mixture was pre-absorbed onto flash silica and eluted with 20-40% EtOAc/petroleum ether 40/60 (v:v). N-(5-Bromo-pyridin-3-yl)-2-[3-(tert-butyl-dimethyl-silanyloxy)-phenyl]-acetamide was isolated in 48% yield.
LC-MS, m/z [MH]+ 421. Retention time, 2.86 minutes. Method B.
1H NMR (DMSO-Cf6, 400 MHz): δ=0.00 (s, 6H, (CHa)2), 0.78 (s, 9H1 (CH3)3), 3.47 (s, 2H, CH2), 6.57 (d, 1H, Ar—H), 6.68 (s, 1H, Ar—H), 6.75 (d, 1H, Ar—H), 7.03 (t, 1H1 Ar—H)18.21 (s s, 2H, Ar—H), 8.50 (s, 1H, Ar—H), 10.42 (s, 1H, N—H).
To a solution of N-(5-bromo-pyridin-3-yl)-2-[3-(tert-butyl-dimethyl-silanyloxy)-phenyl]-acetamide 1.29 g, 3.07 mmol) in de-gassed DMF (15 ml) under a N2 atmosphere, 3-hydroxyphenyl boronic acid (846 mg, 6.14 mmol), NaHCO3 (1-03 g, 12.28 mmol), de-gassed de-ionised water (5 ml), triphenylphosphine (121 mg, 0.46 mmol) and palladium acetate (35 mg, 0.15 mmol) were added. Reaction was stirred at 80° C. for 18 hours. Reaction was cooled and evaporated to dryness. Residue was dissolved in EtOAc (40 ml) and washed Na2CO3 (30 ml) and de-ionised water (30 ml), dried over MgSO4, filtered and evaporated to dryness. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica and eluted with 5-10% MeOH/DCM. Product was triturated in diethyl ether. Compound 256 was isolated in a 46% yield.
LC-MS, m/z [MH]▪ 381. Retention time, 1.41 minutes. Method B.
1H NMR (DMSO-de, 400 MHz): δ=3.43 (s, 2H, CH2), 6.50 (d, 1H, Ar—H), 6.60 (m, 3H, Ar—H), 6.68 (d, 1H, Ar—H)1 6.84 (s, 1H1Ar—H), 6.95 (m, 2H, Ar—H)1 8.14 (s, 1H, Ar—H)1 8.32 (s, 1H, Ar—H), 8.53 (s, 1H, Ar—H), 9.21 (s, 1H1OH), 9.50 (s, 1H, OH)1 10.31 (s1 I H1N—H).
To a solution of 256, 2-(3-hydroxy-phenyl)-N-[5-(3-hydroxy-phenyl)-pyridin-3-yl]-acetamide (190 mg, 0.593 mmol) in THF (10 ml) under a N2 atmosphere, a 2M solution of borane-methyl sulfide complex in THF (1.5 ml, 2.96 mmol) was added in one portion. Reaction was heated under reflux for 2 hours. Mixture was cooled and evaporated to dryness. Residue was dissolved in EtOAc (30 ml) and washed with 10% citric acid (30 ml), NaHCO3 (30 ml) and de-ionised water (30 ml), dried over MgSO4, filtered and evaporated under vacuum. Residue was dissolved in EtOH (30 ml) and heated under reflux for 3 hours. Mixture was cooled and evaporated to dryness. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica and eluted with 5-10% MeOH/DCM. Compound 244 was isolated in a 31% yield.
LC-MS, m/z [MH]+ 307. Retention time, 1.62 minutes. Method B.
1H NMR (DMSO-c/e, 400 MHz): δ=2.70 (t, 2H, CH2), 3.20 (t, 2H, CH2), 5.90 (t, 1H, N—H), 6.49 (d, 1H, Ar—H), 6.58 (s, 1H, Ar—H), 6.70 (d, 1H1Ar—H), 6.78 (d, 1H, Ar—H), 6.90 (s, 1H, Ar—H), 6.94 (m, 2H, Ar—H), 7.00 (t, 1H, Ar—H), 7.15 (t, 1H, Ar—H) 7.88 (d, 2H), 9.15 (s, 1H, OH), 9.41 (s, 1H, OH).
To a suspension of 4-methyl-3-methoxy benzoic acid (480 mg, 2.9 mmol), 3-bromo-5-amino pyridine (500 mg, 2.9 mmol) and NEt3 (604 μl, 3.44 mmol) in THF (10 ml) at room temperature under a N2 atmosphere, HBTU (1.10 g, 2.90 mmol) was added. Reaction was stirred for 30 minutes before being warmed to 50° C. and stirred for 18 hours. Solvent was removed under vacuum, residue was dissolved in EtOAc (30 ml) and washed with 10% citric acid (30 ml), Na2CO3 (30 ml), de-ionised water (30 ml) and brine (30 ml), dried over MgSO4, filtered and evaporated. Residue was purified by column chromatography. Mixture was pre absorbed onto flash silica and eluted with 40% EtOAc/petroleum ether 40/60 (v:v). N-(5-Bromo-pyridin-3-yl)-3-methoxy-4-methyl-benzamide was isolated in 52% yield.
LC-MS, m/z[MH]+ 321. Retention time, 2.14 minutes, Method B.
1H NMR (DMSO-Of6, 400 MHz): δ=2.02 (s, 3H, CH3), 3.67 (s, 3H, CH3), 7.11 (d, 1H, Ar—H), 7.27 (s, 1H1 Ar—H), 7.30 (d, 1H, Ar—H), 8.21 (s, 1H, Ar—H), 8.30 (s, 1H, Ar—H), 8.70 (s, 1H, Ar—H), 10.29 (s, 1H, NH).
To a solution of N-(5-bromo-pyridin-3-yl)-3-methoxy-4-methyl-benzamide (482 mg, 1.50 mmol) in de-gassed DMF (8 ml) under a N2 atmosphere, 3-hydroxyphenyl boronic acid (414 mg, 3.8 mmol), NaHCO3 (504 mg, 6.00 mmol), de-gassed de-ionised water (4 ml), triphenylphosphine (59 mg, 0.22 mmol) and palladium acetate (17 mg, 0.073 mmol) were added. Reaction was stirred at 80° C. for 18 hours. Reaction was cooled and evaporated to dryness. Residue was dissolved in EtOAc (40 ml) and washed with Na2CO3 (30 ml) and de-ionised water (30 ml), dried over MgSO4, filtered and evaporated to dryness. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica and eluted with 5% MeOH/DCM. Compound 267 was isolated in a 95% yield.
LC-MS, m/z [MH]+ 335. Retention time, 1.89 minutes. Method B.
1H NMR (DMSO-CZ6, 400 MHz): δ=3.42 (s, 3H, CH3), 4.10 (s, 3H, CH3), 7.05 (d, 1H, Ar—H), 7.25 (s, 1H, Ar—H), 7.32 (d, 1H, Ar—H), 7.53 (t, 2H, Ar—H) 7.72 (s, 1H, Ar—H), 7.78 (d, 1H, Ar—H), 8.62 (s, 1H, Ar—H), 8.87 (s, 1H, Ar—H), 9.12 (s, 1H, Ar—H) 9.85 (s, 1H, OH), 10.65 (s, 1H, NH).
To a solution of N-[5-(3-hydroxy-phenyl)-pyridin-3-yl]-3-methoxy-4-methyl-benzamide (267) (474 mg, 1.42 mmol) in THF (10 ml) under a N2 atmosphere, a 2M solution of borane-methyl sulfide complex in THF (3.54 ml, 7.10 mmol) was added in one portion. Reaction was heated under reflux for 2 hours. Mixture was cooled and evaporated to dryness. Residue was dissolved in EtOAc (30 ml) and washed with 10% citric acid (30 ml), NaHCO3 (30 ml) and de-ionised water (30 ml), dried over MgSO4, filtered and evaporated under vacuum. Residue was dissolved in EtOH (30 ml) and heated under reflux for 3 hours. Mixture was cooled and evaporated under vacuum. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica and eluted with 5% MeOH/DCM. Compound 268 was isolated in a 37% yield.
LC-MS1 m/z [MH]+ 321. Retention time, 2.32 minutes. Method B.
1H NMR (DMSO-c/e, 400 MHz): δ=2.15 (s, 3H, CH3), 3.81 (s, 3H, CH3), 4.35 (d, 2H, CH2) 6.60 (t, 1H, N—H), 6.84 (d, 1H1Ar—H), 6.95 (d, 1H, Ar—H), 7.00 (s, 1H, Ar—H) 7.04 (m, 2H1 Ar—H), 7.10 (m, 2H, Ar—H), 7.28 (t, 1H, Ar—H), 8.00 (s, 2H, Ar—H), 9.60 (s, 1H, OH).
To a solution of 3-[5-(3-methoxy-4-methyl-benzylamino)-pyridin-3-yl]-phenol (268) (163 mg, 0.51 mmol) in DCM (10 ml) at −78° C. under a N2 atmosphere, borontribromide (800 μl, 1.17 mmol) was added. Reaction was allowed to warm to room temperature and stirred for 18 hours. Reaction was quenched with addition of de-ionised water and adjusted to pH 6 by addition of 2M NaOH. Mixture was extracted with EtOAc (2×40 ml). The organic phases were combined, dried over MgSO4 and evaporated to dryness. Residue was purified by Prep-HPLC. Compound 247 was isolated in 43% yield.
LC-MS, m/z [MH]+ 307. Retention time, 1.58 minutes. Method B.
1H NMR (DMSO-CZ6, 400 MHz): δ=2.22 (s, 3H, CH3), 4.41 (d, 2H, CH2) 6.75 (t, 1H, N—H), 6.91 (d, 1H, Ar—H), 7.70 (s, d, 2H, Ar—H)1 7.11 (s, 1H, Ar—H) 7.20 (m, 3H, Ar—H), 7.42 (t, 1H1Ar—H), 8.12 (d, 2H1Ar—H)19.35 (s, 1H1O—H), 9.70 (s, 1H1O—H).
To a solution of 3-amino-5-bromo pyridine (500 mg, 2.89 mmol) and NEt3 in THF (5 ml), a solution of acetic acid 3-chlorocarbonyl-2-methyl-phenyl ester (614 mg, 2.89 mmol) in THF (5 ml) was added dropwise. Reaction was stirred for 18 hours at room temperature. Solvent was removed under vacuum. Residue was dissolved in EtOAc (30 ml) and extracted with 10% citric acid (30 ml), de-ionised water (30 ml), 1M NaOH (30 ml) and brine (30 ml), dried over MgSO4 filtered and evaporated. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica and eluted with 50% EtOAc/petroleum ether 40/60 (v:v). 3-(5-Bromo-pyridin-3-yl-carbamoyl)-2-methyl-phenyl-acetate was isolated in a 51% yield.
LC-MS, m/z [MH]+ 349. Retention time, 1.89 minutes. Method B.
1H NMR (CDCl3, 400 MHz): δ=2.26 (s, 3H, CH3), 2.29 (s, 3H, CH3), 7.11 (d, 1H, Ar—H), 7.25 (m, 2H, Ar—H), 8.18 (s, 1H, Ar—H), 8.41 (s, 1H, Ar—H), 8.72 (d, 2H, Ar—H, N—H).
To a solution of 3-(5-bromo-pyridin-3-yl carbamoyl)-2-methyl phenyl acetate (542 mg, 1.55 mmol) in de-gassed DMF (8 ml) under a N2 atmosphere, 3-hydroxyphenyl boronic acid (428 mg, 3.10 mmol), NaHCO3 (522 mg, 6.20 mmol), de-gassed de-ionised water (4 ml), triphenylphosphine (61 mg, 0.23 mmol) and palladium acetate (17 mg, o.oδmmol) were added. Reaction was stirred at 80° C. for 18 hours. Reaction was cooled and evaporated to dryness. Residue was dissolved in EtOAc (40 ml) and washed Na2CO3 (30 ml) and de-ionised water (30 ml), dried over MgSO4, filtered and evaporated to dryness. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica and eluted with 10% MeOH/DCM. Compound 269 was isolated in a 75% yield.
LC-MS, m/z [MH]+ 321. Retention time, 1.45 minutes. Method B.
1H NMR (DMSO-Gf6, 400 MHz): δ=2.09 (s, 3H, CH3), 6.85 (d, 1H, Ar—H), 6.89 (d, 2H, Ar—H), 6.98 (s, 1H, Ar—H), 7.04 (m, 2H1 Ar—H), 7.24 (t, 1H, Ar—H), 8.32 (s, 1H, Ar—H), 8.45 (s, 1H, Ar—H), 8.75 (s, 1H, Ar—H), 9.51 (d, 1H, O—H), 9.53 (s, 1H, O—H), 10.45 (s, 1H1N—H).
To a solution of 3-hydroxy-N-[5-(3-hydroxy-phenyl)-pyridin-3-yl]-2-methyl-benzamide (269) (373 mg, 1.16 mmol) in THF (10 ml) under a N2 atmosphere, a 2M solution of borane-methyl sulfide complex in THF (2.91 ml, 5.80 mmol) was added in one portion. Reaction was heated under reflux for 2 hours. Mixture was cooled and evaporated to dryness. Residue was dissolved in EtOAc (30 ml) and washed with 10% citric acid (30 ml), NaHCO3 (30 ml) and de-ionised water (30 ml), dried over MgSO-t, filtered and evaporated under vacuum. Residue was dissolved in EtOH (30 ml) and heated under reflux for 3 hours. Mixture was cooled and evaporated. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica and eluted with 5% MeOH/DCM. Compound 233 was isolated in a 31% yield.
LC-MS, m/z [MH]+ 307 Retention time, 1.63 minutes, Method B.
1H NMR (DMSO-CZ6, 400 MHz): δ=2.20 (s, 3H, CH3), 4.35 (d, 2H, CH2), 6.42 (t, 1H, N—H), 6.80 (d, 1H, Ar—H), 6.90 (d, 1H, Ar—H), 7.02 (s, 1H, Ar—H), 7.08 (d, 1H, Ar—H), 7.12 (s, 1H, Ar—H), 7.32 (t, 1H, Ar—H), 8.05 (s, 2H, Ar—H), 9.30 (s, 1H1O—H), 9.62 (s, 1H, O—H).
Sodium triacetoxyborohydride (1.72 g, 8.15 mmol) was added to a mixture of 3-methoxy benzaldehyde (707 μl, 5.28 mmol) and 3-amino-5-bromo pyridine (1 g, 5.82 mmol) in DCM (20 ml). The reaction was stirred at room temperature for 18 hours. Reaction was diluted with DCM (60 ml) and washed with de-ionised water (2×60 ml). Aqueous phases were combined and extracted with EtOAc (3×60 ml). Organic phases were combined, dried over MgSO4, filtered and evaporated to dryness. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica, loaded onto a 10 g isolute flash Si cartridge and eluted using CombiFlash™ instrumentation, with a gradient of 0-100% EtOAc/petroleum ether 40/60 (v:v). (5-Bromo-pyridin-3-yl)-(3-methoxy-benzyl)-amine was isolated in 78% yield.
LC-MS, m/z [MH]+ 293. Retention time, 2.07 minutes. Method B.
1H NMR (DMSO-Cf6, 400 MHz): δ=3.60 (s, 3H, CH3), 4.15 (d, 2H, CH2), 6.70-6.98 (5H, Ar—H, NH), 7.12 (t, 1H, Ar—H), 7.65 (s, 1H, Ar—H), 7.80 (s, 1H, Ar—H).
To a solution of (5-bromo-pyridin-3-yl)-(3-methoxy-benzyl)-amine (450 mg, 1.54 mmol) in DMF (5 ml) under a N2 atmosphere at 0° C., sodium hydride (60% dispersed in mineral oil, 74 mg, 1.85 mmol) was added. Reaction was stirred at 0° C. for 30 minutes. Methyl iodide (210 μl, 3.28 mmol) was added and reaction allowed to warm to room temperature and stirred for 2 hours. Reaction was evaporated to dryness. Residue was dissolved in EtOAc (40 ml) and washed with de-ionised water (40 ml), dried over MgSO4, filtered and evaporated. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica, loaded onto a 10 g isolute flash Si cartridge and eluted using CombiFlash™ instrumentation, with a gradient of 0-65% EtOAc/petroleum ether 40/60 (v:v). (5-bromo-pyridin-3-yl)-(3-methoxy-benzyl)-methyl-amine was isolated in 37% yield.
LC-MS, m/z[MH]+ 307. Retention time, 2.28 minutes. Method B.
1H NMR (DMSO-CZ6, 400 MHz): δ=2.88 (s, 3H, N—CH3), 3.51 (s, 3H, OCH3), 4.41 (s, 2H, CH2), 6.55 (m, 2H, Ar—H), 6.63 (d, 1H, Ar—H), 7.05 (m, 2H, Ar—H), 7.68 (s, 1H1Ar—H), 7.85 (s, 1H1Ar—H).
To a solution of (5-bromo-pyridin-3-yl)-(3-methoxy-benzyl)-methyl-amine (160 mg, 0.52 mmol) in de-gassed DMF (10 ml) under a N2 atmosphere, 3-hydroxyphenyl boronic acid (144 mg, 1.04 mmol), NaHCO3 (175 mg, 2.10 mmol), de-gassed de-ionised water (5 ml), triphenylphosphine (21 mg, 0.078 mmol) and palladium acetate (6 mg, 0.026 mmol) were added. Reaction was stirred at 80° C. for 18 hours. Reaction was cooled and evaporated to dryness. Residue was dissolved in EtOAc (40 ml) and washed with Na2CO3 (30 ml) and de-ionised water (30 ml), dried over MgSO4, filtered and evaporated to dryness. Residue was purified by flash chromatography. Mixture was pre absorbed onto flash silica, loaded onto a 10 g isolute flash Si cartridge and eluted using CombiFlash™ instrumentation, with a gradient of 0-100% EtOAc/petroleum ether 40/60 (v:v). Compound 261 was isolated in 75% yield.
LC-MS, m/z[MH]+ 321. Retention time, 2.00 minutes. Method B.
1H NMR (DMSO-cfe, 400 MHz): δ=3.10 (s, 3H, N—CH3), 3.70 (s, 3H, O—CH3), 4.65 (s, 2H, CH2), 6.79 (m, 4H, Ar—H), 6.98 (s, 1H, Ar—H), 7.01 (d, 1H, Ar—H), 7.13 (s, 1H1Ar—H), 7.21 (m, 2H, Ar—H), 8.03 (s, 2H, Ar—H), 9.52 (s, 1H, OH).
To a solution of 3-{5-[(3-methoxy-benzyl)-methyl-amino]-pyridin-3-yl}-phenol (261) (75 mg, 0.23 mmol) in DCM (15 ml) at −78° C. under a N2 atmosphere, boron tribromide (800 μl, 1.17 mmol) was added. Reaction was allowed to warm to room temperature and stirred for 18 hours. Reaction was quenched with addition of de-ionised water and adjusted to pH6 by addition of 2M NaOH. Mixture was extracted with EtOAc (2×40 ml). The organic phases were combined, dried over MgSO4 and evaporated to dryness. Compound 241 was isolated in 57% yield.
LC-MS, m/z [MH]+ 305. Retention time, 1.60 minutes. Method B.
1H NMR (DMSO-d6, 400 MHz): δ=3.07 (s, 3H, N—CH3), 4.58 (s, 2H, CH2), 6.56 (d, 2H, Ar—H), 6.60 (d, 1H, Ar—H), 6.74 (d, 1H, Ar—H)1 6.97 (s, 1H, Ar—H), 7.01 (d, 1H, Ar—H), 7.10 (m, 2H, Ar—H)1 7.21 (t, 1H, Ar—H), 8.02 (s, 2H1Ar—H)1 9.30 (s, 1H, OH)1 9.52 (S1 1H1OH).
Sodium triacetoxyborohydride (664 mg, 2.97 mmol) was added to a mixture of 3-hydroxy benzaldehyde (285 mg, 2.34 mmol) and 3-amino pyridine (200 mg, 2.13 mmol) in DCM (10 ml). The reaction was stirred at room temperature for 18 hours. Reaction mixture was diluted with DCM (30 ml) and washed with de-ionised water (2×20 ml). Aqueous phase was combined and extracted with EtOAc (3×30 ml). The organic phases were combined, dried over MgSO4, filtered and evaporated. Residue was purified by column chromatography. Mixture was pre absorbed onto flash silica and eluted with 80% EtOAc/petroleum ether 40/60 (v:v). Compound 257 was isolated in 52% yield.
LC-MS1 m/z [MH]+ 201. Retention time, 1.32 minutes. Method B.
1H NMR (DMSO-de, 400 MHz): δ=4.35 (d, 2H1CH2), 6.62 (t, 1H1N—H)1 6.75 (d, 1H, Ar—H), 6.90 (s, 1H1Ar—H)1 6.95 (s, 1H, Ar—H)1 7.00 (d, 1H1Ar—H)1 7.19 (d, 1H, Ar—H)1 7.30 (t, 1H1Ar—H), 7.90 (d, 1H, Ar—H)1 8.11 (s, 1H, Ar—H)1 9.49 (s, 1H1OH).
To a solution of (5-bromo-pyridin-3-yl)-(3-methoxy-benzyl)-amine (1.35 g, 4.62 mmol) in dry DCM (20 ml), DMAP (135 mg), and Et3N (966 μl, 6.93 mmol) was added followed by dropwise addition of a solution of di-tert-butyl dicarbonate (2.26 g, 10.35 mmol), in dry DCM (20 ml). Reaction was stirred at room temperature for 24 hours. Mixture was evaporated, dissolved in EtOAc (30 ml) and washed with 10% citric acid (30 ml), 1M NaOH (2×30 ml), de-ionised water (30 ml) and brine (30 ml). The organic phases were dried over MgSO4, filtered and evaporated. (5-Bromo-pyridin-3-yl)-(3-methoxy-benzyl)-carbamic acid tert-butyl ester was isolated in 67% yield.
LC-MS, m/z [MH]+ 393. Retention time, 2.56 minutes. Method B.
1H NMR (DMSO-de, 400 MHz): δ=1.45 (s, 9H, t-butyl), 3.79 (s, 3H, O—CH3), 4.81 (s, 2H, CH2), 6.80 (m, 3H, Ar—H), 7.25 (t, 1H, Ar—H), 7.74 (s, 1H, Ar—H), 8.40 (s, 1H, Ar—H), 7.48 (s, 1H1Ar—H).
To a suspension of Zinc (218 mg, 3.2 mmol) in dry THF (5 ml) under a N2 atmosphere, dibromoethane (19.2 μl, 0.22 mmol) was added. Reaction was heated at 60° C. for 5 minutes then allowed to cool to 35° C. Chlorotrimethylsilane (58 μl, 0.45 mmol) was added and mixture was stirred for 30 minutes followed by addition of 3-methoxybenzylbromide (234 μl, 1.67 mmol). Reaction was allowed to stir for 30 minutes. A solution of (δ-bromo-pyridin-S-ylHS-methoxy-benzyO-carbamic acid tert-butyl ester (219 mg, 0.56 mmol) and tetrakis(triphenylphosphine) palladium (0) (16 mg 0.014 mmol) in dry THF (3 ml) was added and reaction was stirred for 40 minutes at 50° C. Reaction was cooled, filtered through celite, diluted with EtOAc (20 ml) and washed with NH4Cl (15 ml), and brine (15 ml), dried over MgSO4, filtered and evaporated. Residue was purified by column chromatography. Mixture was pre absorbed onto flash silica and eluted with 5% MeOH/DCM. Compound 270 was isolated in 20% yield.
LC-MS, m/z[MH]+ 435. Retention time, 2.17 minutes. Method A.
1H NMR (CDCl3, 400 MHz): δ=1.38 (s, 9H, t-butyl), 3.75 (s, 3H, O—CH3), 3.78 (s, 3H, O—CH3), 3.88 (s, 2H, CH2), 4.77 (s, 2H, CH2), 6.70 (m, 6H, Ar—H), 7.20 (m, 3H, Ar—H), 8.28 (s, 1H, Ar—H), 8.30 (s, 1H, Ar—H).
To a solution of (3-methoxy-benzyl)-[5-(3-methoxy-benzyl)-pyridin-3-yl]-carbamic acid tert-butyl ester (270) (48 mg, 0.011 mmol) in DCM (2 ml) and de-ionised water (0.5 ml), TFA (2 ml) was added. Reaction was stirred for 1 hour at room temperature. Reaction was evaporated to dryness and partitioned between NaHCO3 (30 ml) and EtOAc (30 ml). Aqueous phase was removed and further extracted with EtOAc (2×30 ml). The organic phases were combined, dried over MgSO4, filtered and evaporated. Compound 271 was isolated in 71% yield.
LC-MS, m/z[MH]+ 335. Retention time, 2.18 minutes, Method B.
1H NMR (CDCl3, 400 MHz): δ=3.78 (s, 3H, O—CH3), 3.80 (s, 2H, O—CH3), 3.82 (s, 2H, CH2), 4.03 (br s, 1H, N—H), 4.26 (d, 2H, CH2), 5.99 (s, 1H, Ar—H), 6.73 (s, 1H, Ar—H), 6.80 (d, 2H, Ar—H), 6.83 (d, 1H, Ar—H), 6.90 (s, 1H, Ar—H), 6.93 (d, 1H, Ar—H), 7.24 (m, 2H, Ar—H), 7.91 (s, 1H, Ar—H), 7.95 (s, 1H, Ar—H).
To a solution of (3-methoxy-benzyl)-[5-(3-methoxy-benzyl)-pyridin-3-yl]-amine (271) (29 mg, 0.086 mmol) in DCM (2 ml) at −78° C. under a N2 atmosphere, a 2M solution of boron tribromide in DCM (2.72 ml, 2.72 mmol) was added dropwise. Reaction was allowed to rise to room temperature and stirred for 1 hour. Reaction was quenched with NaHCO3 (5 ml) and extracted with EtOAc (3×30 ml). The organic phases were combined, washed with brine (50 ml), dried over MgSO4, filtered and evaporated. Residue was purified by column chromatography. Mixture was pre absorbed onto flash silica and eluted with 10% MeOH/DCM. Compound 272 was isolated in 40% yield.
LC-MS, m/z [MH]+ 307. Retention time, 1.34 minutes. Method B.
1H NMR (DMSO-de, 400 MHz): δ=3.79 (s, 2H1 CH2), 4.25 (s, 2H, CH2), 6.68-7.10 (9H, Ar—H, N—H).
One skilled in the art readily appreciates that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and reagents described herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Modifications therein and other uses will occur to those skilled in the art. These modifications are encompassed within the spirit of the invention and are defined by the scope of the claims.
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. Those skilled in the art will also recognize that all combinations of embodiments, combination of aspects or features of the claims described herein are within the scope of the invention.
| Number | Date | Country | Kind |
|---|---|---|---|
| 04018131.5 | Jul 2004 | EP | regional |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2005/008321 | 8/1/2005 | WO | 00 | 7/22/2007 |
| Number | Date | Country | |
|---|---|---|---|
| 60599307 | Aug 2004 | US |
